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1 Summary 
 
ErbB2 is an orphan receptor tyrosine kinase which can dimerize with other ligand-activated 
members of the EGF receptor family to signal in pathways inducing cell proliferation.  
Frequently overexpressed in breast cancer and other human cancers, homologs of ErbB2 are 
oncogenes in different animal species which have been studied for their contribution to the 
development of carcinomas.  
The first part of this project was aimed at developing a method for vaccination of 
mouse, so that a transplanted tumor expressing the endogenous mouse c-erbB2 would be 
rejected.  Initially, it was necessary to prepare a functional expression clone of mouse c-
erbB2.  Then the question of how to break the natural tolerance against an immune response 
against the self-antigen, mouse c-erbB2, had to be approached.  Several protocols were 
attempted as described below, but I was unsuccessful in obtaining the intended protective 
effect against transplanted tumor.  
In the second part of this work, we have examined phenotypes induced by several 
ErbB2 homologs in Line 31E mouse mammary epithelial cells which are capable of 
differentiation in vitro to undergo dome formation and to produce milk protein in response to 
lactogenic hormones. Included in this comparative study are the functional clone of the mouse 
proto-oncogene c-erbB2, a human homolog overexpressed in breast cancer, HER2, and the 
mutated rat homolog, NeuT, which is known to be oncogenic. 
Line 31E mammary epithelial cells were infected with retroviral pBabe
puro
 constructs 
of the different ErbB2 homologs.  Typical features of epithelial intercellular organization, 
such as density of tight junctions and dome formation, were disturbed by ErbB2 expression.  
While a dominant negative mutant of HER2 had no effect on the epithelial cells, both 
transepithelial monolayer resistance and dome formation were reduced by all three of the 
functional ErbB2 homologs, most dramatically by NeuT.  While expression of both the mouse 
proto-oncogene c-erbB2 and HER2 resulted in significant inhibition of β-casein mRNA and 
protein levels after lactogenic hormone treatment, NeuT completely abrogated β-casein 
production and caused oncogenic transformation as evidenced by large colonies in soft agar 
and Matrigel suspension culture. While the cells expressing the homologs remain acutely 
responsive to EGF ligand in terms of Akt/PKB, ERK 1/2 and PKCα phosphorylation, an 
elevated basal phosphorylation in the absence of ligand was not apparent for PKCα.    
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2 Aims of the study 
 
Part I: 
Our goal was to test the hypothesis that the natural tolerance to the endogenous mouse c-
erbB2 could be overcome by vaccination with the xenogeneic human homologue HER2. 
Vaccination experiments have already been shown to be successful in transgenic mice 
constitutively overexpressing the oncogenic rat homologue NeuT under the control of an 
exogenous promoter [2]. However, in this case, the immunity achieved was of course specific 
for the rat gene in mutated form, ie NeuT. Here we try to adapt this approach to achieve a 
theoretical vaccination against HER2 in human breast cancer. To test this concept, we 
immunized mice with HER2, a closely related, but foreign homolog, then challenged with a 
mouse tumor transplantation model expressing the endogenous c-erbB2 of the mouse. 
Ultimately, using this system, we also were unable to demonstrate an effective immunization 
or protective effect. 
 
Part II: 
The aim in part II is to characterize the phenotypes of endogenous mouse c-erbB2 (the normal 
endogenous gene occurring in healthy mice), of human HER2 (deriving from a tumor) and of 
NeuT (derived from a rat tumor) in mouse mammary cells in culture. Cell signaling and in 
vitro differentiation in response to lactogenic hormones were investigated. 
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3 Introduction 
3.1 Human Breast Cancer 
3.1.1 Background 
 
In Switzerland, cancer is the most frequent cause of death below the age of 75 [3]. The 
dominating malignancy in women is the mammary carcinoma with 30% of all cancer, leading 
to more than 1300 cases of death per year [3,4]. Breast cancer is diagnosed in about 4000 
women in Switzerland per year and in about 250’000 in Europe and its occurrence is steadily 
increasing (websites 1 and 2). The aetiology is unknown but numerous risk factors have been 
described so far. Only 5% of mammary carcinomas follow a hereditary pattern, mutations in 
tumor-suppressor genes (BRCA-1 and BRCA-2) can be detected in most of these cases. Other 
risk factors are early menarche, late menopause, childlessness, hormone substitution in 
menopause, obesity, smoking and excessive alcohol consumption [4]. However, the majority 
of patients with breast cancer (up to 95%) develop the disease “spontaneously”, with no risk 
factor being explicitly identified (website 2). The mortality is around 25% for breast cancer in 
Switzerland. Following the first treatment approximately half of the patients develop 
metastatic disease. The standard treatments for breast cancer so far have been chemotherapy, 
radiation, surgery and hormone therapy. These treatments are given with the goals of curing 
the cancer and/or limiting its spread, and providing relief from symptoms (website 1). 
The adult mammary epithelium is organized into ducts and lobules. The ducts end in a 
highly branched structure, the terminal ductal lobular unit (TDLU). A TDLU consists of 
multiple individual units referred to as mammary acini. Each acinus has a central lumen, a 
single layer of polarized luminal epithelial cells surrounded by myoepithelial cells, and a 
basement membrane [5]. Breast cancer emerges through a multistep process progressing from 
hyperplasia to premalignant change, in situ carcinoma, and invasive breast cancer [6]. In 
ductal breast cancer the tumor arises from the lining of the milk ducts, as opposed to the 
lobules of the breast in lobular breast cancer [7]. Early stages of breast cancer (hyperplasia 
and ductal carcinoma in situ (DCIS)) are characterized by an increased proliferation of 
epithelial cells, a loss of acinar organization and filling of the luminal space. However, a lack 
of acinar organization and the acquisition of invasive behaviour are later events involved in 
progression towards malignancy [5]. 
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3.1.2 The HER2 positive mammary carcinoma 
 
Several types of cancers overexpress HER2. In breast cancer the protein is overexpressed 
owing to gene amplification in 30% of invasive ductal breast cancers [8]. HER2 amplification 
is detected in a high frequency (80–85%) of comedo-type DCIS tumours, which are non-
invasive, premalignant mammary tumours [5]. Furthermore, HER2 is overexpressed in 20-
25% of ovarian cancers, 35-45% of all pancreatic adenocarcinomas, and up to 90% of 
colorectal carcinomas [9]. In breast cancer, overexpression correlates with tumour size, spread 
of the tumour to lymph nodes, high grade, high percentage of S-phase cells, aneuploidy and 
lack of steroid hormone receptors, implying that HER2 confers a strong proliferative 
advantage to tumour cells. Paradoxically, a higher degree of HER2 overexpression is reported 
in early forms of breast cancer relative to more advanced invasive carcinomas, suggesting that 
alterations in HER2 alone are insufficient for breast tumour progression from a relatively 
benign to a more malignant phenotype [7]. 
 Since in this study we are comparing ErbB2 receptors of different species which have 
received different designations, we decided to make clear distinctions: For easier distinction 
we will refer to them as follows: human ErbB2 and mouse c-erbB2 for the physiological non-
mutated version of each of the species, as HER2 to designate the human homologue deriving 
from a tumor where it is overexpressed and for the sake of simplicity, oncogenic rat Neu will 
be referred to as NeuT. 
 
3.1.3 Herceptin, a monoclonal antibody 
 
An approved treatment in HER2 positive breast cancer is the recombinant humanized 
monoclonal antibody (mAb) trastuzumab (Herceptin
®
) targeting the HER2 receptor. 
Trastuzumab is used in therapy either alone (response rates of 26% first-line, resp. 15% post 
chemo) or in combination with cytotoxic chemotherapy (response rate up to 80%) [10]. The 
therapy is generally well tolerated and is not associated with chemotherapy-related side 
effects, such as alopecia, myelosuppression and severe nausea or vomiting [11]. If 
trastuzumab is given in combination with chemotherapy, and in particular with 
anthracyclines, an elevated incidence of cardiotoxicity is observed. There is evidence that this 
side effect reflects an exacerbation of anthracycline-induced cardiotoxicity [11]. Recent work 
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revealed that the inhibition of ErbB2 tyrosine kinase activity in rat cardiomyocytes causes 
MAPK-dependent structural damage in the myocyte contractile apparatus, leading to 
contractile dysfunction of the heart [12]. However, the cardiotoxicity is reversible and can 
usually be managed with standard medical treatment [11]. The clinical benefit from 
trastuzumab seems to be outstanding in the history of cancer treatment [13]. Trastuzumab was 
tested as an adjuvant to chemotherapy and in a one year treatment after surgery and 
chemotherapy. It was shown to dramatically reduce the risk of recurrence in women with 
HER2-positive breast cancer. Furthermore, the overall events (recurrence, second primary 
cancer or death before recurrence) were reduced by almost 50% in the trastuzumab treated 
group versus control, as was reported in recently published phase III trials [14,15].  
It has been shown experimentally that the activity of trastuzumab is limited to ErbB2 
homodimers. Binding of the mAb to ErbB2 homodimers rapidly downregulates PI3K/Akt, 
MAPK, Src and STAT signaling, and blocks the proliferation of tumor cell lines in nude mice 
[16]. However, the possible mechanisms of action of trastuzumab are numerous and can be 
attributed to extracellular and intracellular effects [17]. In contrast, trastuzumab can block 
neither the ligand-induced formation of ErbB2 heterodimers nor the heterodimer-induced 
activation of downstream signaling pathways. This characteristic could be a possible 
explanation for resistance to therapy [16]. In order to improve the inhibiting effect, 
pertuzumab, another humanized monoclonal antibody against ErbB2 has been developed and 
is in phase II trials at present. Pertuzumab is supposed to bind ErbB2 on the domain II 
dimerization arm (see chapter 3.3.1 and Fig. 2 for details) thereby preventing the formation 
of ligand-induced ErbB2 heterodimers [16]. 
  In fact, 70% of patients are unresponsive from the start of trastuzumab treatment and 
nearly all eventually become unresponsive during treatment. These failures could depend on 
impairment of the machinery responsible for receptor downregulation, as it is known for 
autocrine TGFα production. By in vitro expression of exogenous TGFα in breast cancer cells, 
a dramatic reduction in trastuzumab-induced HER2 endocytosis, downregulation and cell 
growth inhibition could be observed. These findings were supported by selective cases in 
vivo, by comparing breast cancer neoplastic tissue before and after trastuzumab treatment. 
TGFα expression is not significantly induced upon treatment with trastuzumab [18]. 
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3.1.4 Small-molecule tyrosine-kinase inhibitors 
 
The small-molecule tyrosine-kinase inhibitors (TKIs) represent a distinct type of ErbB2 
inhibitors that compete with ATP in the tyrosine-kinase domain of the receptor. So far two 
dual kinase inhibitors, blocking simultaneously both receptors, ErbB2 and EGFR, are being 
tested on ErbB2 positive breast cancer: the reversible inhibitor Lapatinib is being tested in 
phase III trials and the irreversible inhibitor CI-1033 has reached phase II trials. Both TKIs 
were shown to suppress tumor growth via the same pathways as with trastuzumab interaction. 
Although clinical efficacy of these inhibitors have been shown, the effects in patients can 
often not compete with the optimistic predictions from preclinical studies [16].  
 
 
3.2 Part I – A xenogeneic HER2 DNA vaccination approach 
 
3.2.1 Why a tumor vaccination should be investigated 
 
Conventional cancer treatments including surgery, chemotherapy, and radiation are highly 
invasive and sometimes restricted to a palliative effect [19]. A targeted strategy such as a 
cancer vaccine has a much greater selectivity for tumor tissue and a decreased risk of 
collateral toxicity [20]. Many antigen-based vaccines have been successful in animal models 
in which they have been tested almost exclusively in tumor prevention. A reason for the 
failure of some of these strategies in humans is because they are being tested initially as 
therapeutic agents against advanced disease and usually after the failure of standard therapy 
[21]. 
The oncogenic potential of HER2, together with its elevated expression in tumors, cell 
surface localization, and immunogenicity in some patients, make this oncoprotein an ideal 
target for immunotherapeutic approaches [22]. Downregulation of HER2 and later EGFR with 
monoclonal antibodies was the first demonstration of targeted therapy [20]. Natural immunity 
at the level of T and B cells has been observed in patients with ErbB2 overexpressing tumors 
confirming the immunogenicity of ErbB2. ErbB2-specific CTLs can be detected in breast 
cancer patients, but in most cases do not prevent disease progression, which could be 
explained by the induction of tolerance. Antibody immunity to ErbB2 has been shown in 
some patients with early stage breast cancer suggesting that such autoantibodies are induced 
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by the native molecule and they do not simply reflect an increased tumor load or advanced 
stage. Progression of the disease even seems to suppress antibody production. The existence 
of ErbB2-specific T cell immunity in patients suggests that tolerance to ErbB2 has been 
circumvented. Many clinical studies have shown that it is possible to induce T-cell responses 
against ErbB2 peptides in cancer patients, but without engendering a clinical response. 
Peptide-based vaccines generally do not elicit antibody responses [9], which are known to be 
crucial in supporting T cell responses to inhibit ErbB2 positive breast cancer growth [23]. 
Disis et al. [24] stimulated the preexisting immunity of some ErbB2-positive breast cancer 
patients by vaccination with HER2-peptides and the adjuvant GM-CSF without causing 
autoimmunity. The non-occurrence of autoimmunity suggests that ErbB2-specific antibodies 
and T cells generated due to ErbB2 overexpression do not recognize basal ErbB2 expression 
on normal epithelial cells [24]. Immunizations with naked plasmid DNA present a number of 
advantages over peptide-based approaches. Peptide-based vaccines offer only a limited 
number of epitopes, whereas DNA vaccination allows the involvement of multiple different 
antigenic epitopes and a broad range of MHC restriction. Prior knowledge of host haplotype 
is therefore not necessary. Plasmid DNA encoding tumor-associated antigens, once reaching 
the cell nuclei, can persist as a circular episome and is not integrated into the host’s genome. 
This results in a stable long-term expression of the encoded proteins by the host’s cells and a 
permanent stimulation of the immune system, generating a long-lasting immunity. Another 
advantage is the generation of antigen-specific cellular (including CD4+ and CD8+ T cells) as 
well as humoral immune responses because the encoded antigen is processed through both 
endogenous and exogenous pathways. Peptide epitopes are presented by major 
histocompatibility complexes (MHC) class I as well as class II. In addition, DNA vaccines are 
cheap and easy in production and large scale-purification [19]. 
 
3.2.2 The hypothesis of breaking tolerance to endogenous ErbB2 
 
The prerequisite for a successful cancer vaccination is breaking tolerance to the tumor-
associated self-antigen [19]. In FVB mice transgenic for the oncogenic rat NeuT expressed 
under the MMTV-LTR promoter, vaccination with NeuT transfected allogeneic fibroblasts 
induced both T-cell and humoral immune responses and prevented tumor formation [2]. 
Interestingly the results of Pilon et al. [25] were not in accordance with the theory of a 
requirement of both cellular and humoral immune responses to block ErbB2 overexpressing 
tumors [23]. Pilon et al. focussed on inducing only a cellular response to ErbB2 in order to 
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circumvent the postulated harm resulting from an antibody reaction causing cardiac toxicity. 
In prospect of an in vivo application of the DNA vaccine, the tyrosine kinase activity was 
impaired through mutation, a modification which has been shown not to reduce immunogenic 
activity of ErbB2 [26]. The vaccination of non-transgenic mice with human cytoplasmic 
ErbB2 DNA with a deficient tyrosine kinase was revealed to engender an equivalent anti-
tumor activity against human ErbB2 overexpressing tumor cells as to wild-type ErbB2 DNA, 
as long as supported by either GM-CSF or IL-2 DNA, but in contrast did not induce antibody 
response [25]. 
A promising vaccination approach is the injection of xenogeneic DNA. A xenogeneic 
homologue which is highly crossreactive, but not identical to the self antigen presents xeno-
specific determinants that are non-self in the context of the recipients’ immune surveillance; 
the immunological response to these determinants will therefore not suffer from the 
disadvantage of tolerance. A strong CD4 T cell response should be engendered to these 
determinants. According to basic immunology, this strong CD4 T cell response ought to 
stimulate a subset of primary CD8 or cytotoxic T cells (as well as B cells) showing specificity 
for the respective classes of self determinants shared with the xenogeneic product used as the 
vaccine immunogen. If the tumor antigen is a protein with an extracellular domain, this 
strategy profits from a B-cell response additionally. The efficacy of immunization against a 
self antigen using its xenogeneic version has been illustrated for prostatic acid phosphatase 
(PAP) [27], EGFR [28] as well as for ErbB2 [29]. All three examples are shared tumor 
antigens, expressed by both normal and malignant tissue. Prostate cancer patients vaccinated 
with dendritic cells loaded with mouse PAP protein all developed T cell immunity to mouse 
PAP and 50% of the patients showed cross-reactive T cells to the endogenous human PAP, 
which shares 81% homology with the mouse protein on an amino acid level. A subset of the 
patients with cross-reactivity could even profit from a clinical stabilization of their previously 
progressing prostate cancer. In contrast, vaccination with the identical human self antigen 
engendered little or no immunogenicity [27]. In the xenogeneic vaccination approach against 
EGFR, Lu et al. [28] relied on 88% of sequence homology at the amino acid level between 
human and mouse EGFR. In non-transgenic mice, human EGFR DNA induced both 
protective and therapeutic antitumor activity against an EGFR-positive tumor challenge, via 
humoral and cellular immune responses [28]. A xenogeneic DNA vaccination approach, 
consisting of human ErbB2 DNA without any adjuvants, resulted in autoimmunity and 
inhibition of mammary carcinoma development in a NeuT transgenic mouse model. The sera 
of these vaccinated mice revealed high titers of antihuman ErbB2 antibodies which didn’t 
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crossreact with NeuT. No induction of specific CTL activity was observed in splenocytes. 
The vaccine was also given to healthy non-transgenic mice where it elicited autoreactive 
antibodies specific for the endogenous mouse c-erbB2. This data shows that xenogeneic DNA 
immunization can break tolerance against the endogenous mouse c-erbB2. Thus, tumor 
inhibition was explained by autoantibodies reducing the number of normal mammary 
epithelial cells at risk for transformation [29]. 
 
3.2.3 Proposed requirements for eliciting strong CD4/CD8 responses 
 
For achieving the most efficient stimulation of CD4 and CD8 T cells, two leading opinions 
are currently discussed. On the one hand, it is believed that dendritic cells are the most 
powerful antigen presenting cells and that a fibroblast-based vaccine requires cross-
presentation (i.e. transfer of the immunogen from the fibroblast to the dendritic cell in vivo) 
[30]. Ochsenbein and Zinkernagel et al. [31] however, argue that cross-presentation is 
unimportant as long as the fibroblasts are injected directly into a secondary lymphoid organ 
including the spleen and lymph nodes. The importance of targeting ErbB2 tumor antigen to 
antigen-presenting cells (APCs) in order to elicit a strong cell-mediated antitumor immunity 
has recently been demonstrated in non-transgenic mice [32]. Generally, adjuvants are 
believed to be crucial components of all cancer vaccines whether they are composed of whole 
cells, defined proteins or peptides. Adjuvants can activate APCs to stimulate T cells more 
efficiently [21]. Our vaccine design does not include any adjuvant since direct presentation of 
the antigen to the spleen is thought to be sufficient a stimulus for APCs. Without an 
appropriate priming of CTLs by CD4 T cells, the CTLs can remain anergic and nonresponsive 
[31,33]. Anergy is described as a state of antigen-specific nonresponsiveness in which a T or 
B cell is present, but functionally unable to respond to antigen. According to Ochsenbein [34], 
the crucial parameter that drives anti-tumoral immune responses is the antigen dose that 
reaches secondary lymphoid organs over time. If the antigen dose is low, the threshold for the 
activation of CTL within the lymphoid organ may not be reached, resulting in ignorance of 
the antigen. On the other hand a persistent high antigen dose, far above the threshold for CTL 
activation may induce tolerance. Tolerance describes situations where CTL have encountered 
antigen, but are not properly activated or they are actively suppressed by regulatory 
mechanisms. Antigen that is not cleared and persists at high levels in the lymphoid organ first 
activates T cells to proliferate and expand to a peak. T cells do not continue to expand further, 
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but undergo a contraction phase, resulting in the deletion of all T cells specific for that antigen 
[34]. 
To date no one has ever shown that one can effectively induce immune response to 
ErbB2 using the mouse endogenous peptides. The analogy to the work of the Gimmi group 
[2], who achieved a specific immune response against the rat NeuT antigen in transgenic 
mice, fails because it was the rat NeuT which served as the homologue to endogenous human 
HER-2. The mouse model for all such experiments to date have expressed a foreign 
exogenous transgene incorporated into the genome under the control of an exogenous 
promoter [2]. 
 
3.2.4 Our HER2 vaccination strategies 
 
We have the clear aim of overcoming the natural tolerance to mouse endogenous ErbB2 in a 
non-transgenic FVB mouse model. The transplantable tumor model is the Met-1 murine 
mammary tumor line transfected with and expressing at high levels the mouse c-erbB2. To 
facilitate this breaking of tolerance we decided to vaccinate with a xenogeneic homologue, the 
human HER2. The degree of homology between human and mouse c-erbB2 protein has been 
shown to be above 85%. We tried essentially three different protocols to stimulate the 
immune system of the mice. In a first trial, Protocol A, we injected intramuscularly naked 
plasmid DNA carrying human ErbB2. Muscle cells are transfected by the gene and produce a 
protein product. The role of somatic tissues that express plasmid protein may be to serve as a 
reservoir for that antigen which is then transferred to the APCs. It has been shown that the 
mechanism of priming in this method for vaccination uses the MHC from bone marrow-
derived APCs, which are efficient at providing all of the necessary signals for priming T cells 
[35]. In a subsequent series of experiments (Protocol B), we tested FVB fibroblasts as 
syngeneic carrier cells, transfected ex vivo with the xenogeneic homolog and injected directly 
into the spleen. Finally, Protocol C consisted of intrasplenic injections of human ErbB2 DNA. 
The enhanced immune stimulatory effects of the modifications in Protocols B and C have 
been described by Ochsenbein et al. and others [31,32,34], as mentioned above. Protocol C 
was refined by the application of electroporation. Gazdhar et al. [36] showed that the physical 
method of in vivo electroporation is a safe and effective tool for non-viral gene delivery to the 
lungs. Furthermore, it has been demonstrated that electroporation can significantly enhance 
the immunogenicity of a DNA vaccine, resulting in greatly improved antibody responses in 
macaques [37]. The benefit of electroporation has also been demonstrated in intramuscular 
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injections of a NeuT DNA vaccine in NeuT-transgenic FVB mice [38]. Boosters with the 
same dose and the same electroporation treatment in the gastrocnemius muscle of the hind leg 
was described to be effective in rat [37]. As endpoint for all these protocols, we used tumor 
protection against the ErbB2 overexpressing transplantable mouse mammary tumour Met-1. 
While our work was underway we found ErbB2 signaling had been described to act in 
downregulating components of the MHC class I machinery, resulting in an immune escape 
phenotype of the ErbB2 overexpressing cells [39,40]. Since this property would negatively 
affect our vaccination strategy, we engineered a mutation in the HER2 wild type gene, 
resulting in a deletion of the tyrosine kinase activation loop causing its inactivation. In the 
following, we refer to the deleted version of the gene as mutHER2. Early passage FVB 
fibroblast cultures serving as vaccine carriers were thus transfected with and expressing 
mutHER2 at high levels. 
 
 
3.3 Part II – The cell differentiation and signaling pathway project 
 
3.3.1 Molecular properties of EGF receptors 
 
Receptor tyrosine kinases represent a subgroup of the protein kinase family, which is the 
largest enzyme family in humans. Protein kinases catalyze the following reaction: 
 
MgATP
1-
 + protein-OH  →  protein-OPO3
2+
 + MgADP + H
+
 
 
Based upon the nature of the phosphorylated –OH group, these enzymes are classified as 
protein-serine/threonine kinases and protein-tyrosine kinases [41]. Protein-tyrosine kinases 
can be further subdivided into receptor tyrosine kinases, described in more detail below, and 
cellular, or non-receptor tyrosine kinases. The cellular tyrosine kinases are located in the 
cytoplasm or nucleus or are anchored to the inner leaflet of the plasma membrane. Src and Jak 
are exponents of this family [42]. Receptor tyrosine kinases (RTKs) are a superfamily of 
membrane receptors which catalyze the phosphorylation of tyrosine residues and elicit 
cellular effects in a minute timescale. RTKs share a common architecture of an extracellular 
region hosting the ligand-binding domain, a single pass transmembrane domain (approx. 20 
amino acids) and the intracellular catalytic/effector domain incorporating both ATP- and 
substrate-binding sites. The intra- and extracellular domains are usually very large portions of 
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400-700 residues each [43]. The epidermal growth factor (EGF) or ErbB receptors are 
members of the RTK family type I. The family consists of four members: EGF receptor 
(EGFR), also termed ErbB1 (after the v-erbB oncogene of avian erythroblastosis virus)/HER-
1, ErbB2/Neu/HER2 (human EGF receptor 2), ErbB3/HER-3 and ErbB4/HER-4 [41]. The 
four ErbBs share an overall structure of two cysteine-rich domains in their extracellular 
region, and a kinase domain flanked by a carboxy-terminal tail with tyrosine 
autophosphorylation sites [7]. ErbB3 has a tyrosine kinase domain that is highly homologous 
to those of the other family members but its kinase activity is impaired [41]. An overview of 
receptor structures is presented in Figure 1. 
X-ray crystallographic analysis 
revealed the structures of the ErbB 
receptors’ ectodomains in their active 
and inactive conformation and shed 
light on the mechanism of receptor 
activation. The extracellular 
component of all four ErbB proteins 
consists of domains I–IV. The 
activating growth factor, which binds 
to domains I and III, selects and 
stabilizes a conformation that allows a 
dimerization arm to extend from 
domain II to interact with domain II of 
an ErbB dimer partner. 
Crystallographic structures show that 
EGF and TGFα bind to domains I and 
III of a single receptor and do not span 
between two receptors. Ligand binding 
alters the disposition of domains II and 
III but not the relative orientation of 
domains I and II. In the non-activated 
receptor, domain II binds to domain IV, and the dimerization arm is buried and unable to 
interact with an adjacent receptor [44] (Fig. 2).  
 
Fig. 1: Epidermal growth factor family of ligands and the
ErbB gene family. The topology of the receptor proteins is
indicated. The inactive ligand-binding domains of ErbB2 and 
the inactive kinase domain of ErbB3 are denoted with an X. 
Binding specificities of the EGF-related peptide growth 
factors are shown with arrows. There are four categories of 
ligands that bind ErbB family receptors. AR = amphiregulin, 
TGFa = transforming growth factor-a, BTC = betacellulin, 
HB-EGF = heparin-binding EGF, EPR = epiregulin, NRG = 
neuregulins. Figure from Roskoski [41].
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Fig. 2. Ligand induced conformational changes in the EGF receptor ectodomain. The inactive (tethered) EGF 
receptor ectodomain is shown on the left, and the active form is shown on the right. Homologous large (L) 
domains in the receptor (domains I and III) are colored red, and cysteine-rich (CR) domains (domains II and IV) 
are green. Ligand is colored blue. Individual domains are labeled. The mutual linking of the two domain II 
dimerization arms across the dimer interface can be observed in the center of the structure. The speculated 
position of the plasma membrane is depicted as a gray bar. EGF binding requires a 130° rotation of a rigid body 
containing domains I and II about the axis of the domain II/III junction. Figure from Burgess et al. [44]. 
 
 
The conversion of the inactive to active receptor involves a major rotation of the ectodomain, 
since the two ligand-binding sites on domains I and III are too far apart for a single ligand to 
bind to both simultaneously. The stoichiometry for epidermal growth factor binding to 
activated receptor is 2 mol EGF to 2 mol EGFR. The ectodomain of ErbB2, in the absence of 
ligand, resembles the extended conformation of activated ErbB1 suggesting that ErbB2 is 
autoactivated and thus constantly ready to dimerize. The ErbB2 ligand binding site is both 
obstructed and mutated which could serve as an explanation why no specific ligand for this 
receptor has ever been identified [44].  
 
3.3.2 The physiological role of the ErbB signaling network 
 
The importance of ErbB receptors in development is proven from the analysis of genetically 
modified mice. As an example, ErbB2 null mice die at midgestation due to trabeculae 
malformation in the heart, a phenotype that is shared by ErbB4 knockout mice. ErbB 
receptors also play essential roles in the adult organism, as well characterized in the 
proliferation and differentiation of the mammary gland, processes which are mostly 
undergone postnatally. In the mammary gland all four ErbB receptors are expressed in cell 
type- and developmental stage-specific patterns. ErbB2 is expressed in all developmental 
stages and together with ErbB4 it appears to have key roles in lobuloalveolar differentiation 
and lactation. ErbB receptors are activated by a number of ligands, referred to as EGF-related 
peptide growth factors, summarized in Fig. 1. These include EGF, amphiregulin (AR) and 
transforming growth factor α (TGFα), which bind specifically to EGFR, and betacellulin 
(BTC), heparin-binding EGF (HB-EGF) and epiregulin (EPR), which show a dual specificity 
for EGFR and ErbB4. The neuregulins (NRG) make a third ligand family. NRG1, also known 
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as neu-differentiation factor (NDF) or heregulin, and NRG2 both bind ErbB3 and ErbB4, 
whereas NRG3 and NRG4 bind solely ErbB4 [45]. All the ErbB family ligands have in 
common an EGF domain with six conserved cysteine residues characteristically spaced to 
form three intramolecular disulphide bridges. In general, EGF-related peptide growth factors 
are synthesized as glycosylated transmembrane precursors which are proteolytically cleaved 
from the cell surface to become the mature growth factor. EGF and betacellulin, which 
directly bind to the EGFR or ErbB4, mediate signaling through heterodimers of ErbB2 and 
ErbB3 in the absence of the EGFR [46]. Despite intensive efforts no direct ligand for ErbB2 
has yet been discovered. The primary function of ErbB2 seems to be as a coreceptor. In fact, 
ErbB2 is the preferred heterodimerization partner for all other ErbB family members and 
plays a role in the potentiation of ErbB receptor signaling [45]. In earlier times, the 
description of an apparently ErbB2-specific ligand has been reported. It has been isolated and 
characterized as neu-activating factor (NAF), a 15-17 kDa protein, from a transformed human 
T-cell line. NAF is clearly distinguishable from the two other proposed homologous growth 
factors for ErbB2, the neu-differentiation factor (NDF 44 kDa) and heregulin (45 kDa) [47], 
which were later found to be identical, subsequently renamed neuregulin-1 (NRG1) [45]. The 
NAF ligand was reported to specifically interact with the ErbB2 extracellular domain, 
resulting in ErbB2-specific tyrosine kinase activation, homodimerization, internalization, and 
concomitant potentiation of the growth of ErbB2 expressing cell lines. NAF was reported to 
induce ErbB2 tyrosine phosphorylation in a dose-dependent manner in vitro and in vivo, as 
well as its down modulation from the cell surface [47]. Intriguingly, information about this 
proposed specific ErbB2 ligand breaks off in subsequent publications. 
With the exception of EGF, which is found in many body fluids, ErbB ligands 
generally act over short distances as autocrine or paracrine growth factors. In this respect 
ErbB ligands display distinct expression patterns that are organ- and developmental stage-
specific. In the case of the mammary gland, EGFR ligands and NRG-1 are co-expressed at 
various developmental stages. Ligand binding results in receptor dimerization, leading to 
activation of the intrinsic tyrosine kinase and autophosphorylation/transphosphorylation of 
specific, C-terminal tyrosine residues that provide docking sites for proteins containing Src 
homology 2 (SH2) or phosphotyrosine binding (PTB) domains. These include adaptor 
proteins such as Shc and Grb2, but also kinases such as Src and PI3K. The ability of ErB 
ligands to induce not only receptor homodimers but also heterodimers expands ErbB 
signaling potential and signal diversification. ErbB2-containing heterodimers display 
increased ligand affinity due to a decelerated off-rate that can be correlated with prolonged 
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activation of downstream signaling pathways. Furthermore biological responses such as 
proliferation, morphological differentiation and migration/invasion are enhanced in cells 
expressing ErbB2. Olayioye et al. [45] could prove that receptor phosphorylation is 
modulated by the dimerization partner. In addition, despite similar levels of total 
phosphotyrosine, oncogenic ErbB2 homodimers were significantly more potent in binding 
Shc than ErbB2 transphosphorylated by EGF. Thus, the signal elicited by a receptor 
heterodimer is not simply the sum of the signaling properties of the individual dimerization 
partners, but is rather due to unique properties acquired by the heterodimer [45]. Examination 
of the intracellular and extracellular domains of the ErbBs provides a satisfying explanation 
as to why a horizontal network of interactions is crucial to the ErbB signaling pathway: 
ErbB3 is devoid of intrinsic kinase activity, whereas ErbB2 seems to have no direct ligand. 
Therefore, in isolation neither ErbB2 nor ErbB3 can support linear signaling. 
All ErbB family members couple via Shc and/or Grb2 to the mitogen-activated protein 
kinase (MAPK) pathway. Most active ErbB dimers bind and activate the 
phosphatidylinositol-3’-OH kinase (PI3K) [7], a lipid kinase that phosphorylates 3’ hydroxyl 
residues in the inositol rings of certain lipids. These phospholipids act as second messengers 
to recruit and activate downstream targets, including the serine/threonine kinase Akt. This 
phospholipid-binding targets Akt to the cell membrane, where it is phosphorylated and 
activated [48]. The potency and kinetics of PI3K activation can vary, however, probably 
because PI3K couples directly with ErbB3 and ErbB4, but indirectly with ErbB1 and ErbB2 
[7]. Interestingly ErbB2 appears unable to recruit the p85 adaptor subunit of PI3K. Thus, to 
activate this pathway, ErbB2 has either to heterodimerize with another ErbB receptor 
containing a p85 binding site, or activate the pathway indirectly, for example through Ras 
signaling. ErbB3 contains six docking sites for the p85 adaptor subunit of PI3K and 
efficiently couples to this pathway. Furthermore, inactivation of ErbB2 leads to loss of ErbB3 
phosphorylation. These observations suggest that ErbB3’s role in cancer cells might be to act 
as a partner of overexpressed ErbB2 promoting activation of the PI3K/Akt pathway [49]. 
Simultaneous activation of linear cascades, such as the MAPK pathway, the stress-activated 
protein kinase cascade, protein kinase C (PKC) and the Akt pathway translates in the nucleus 
into distinct transcriptional programmes. These involve not only the proto-oncogenes fos, jun 
and myc, but also a family of zinc-finger containing transcription factors that includes Sp1 
and Egr1, as well as Ets family members such as GA-binding protein (GABP) [7]. The 
MAPK signaling pathway is a four-level cascade, in which each kinase activates the 
following kinase substrate through a complex network, enabling the cell to maintain diversity 
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and specificity while responding to various extracellular cues. The MAP kinases JNK and p38 
are activated by a large spectrum of stress-related stimuli, whereas ERK is largely activated 
by growth factor signals [50]. The output of the ErbB network ranges from cell division and 
migration (both associated with tumorigenesis) to adhesion, differentiation and apoptosis [7]. 
A simplified overview of the processes involved in the ErbB signaling network, is depicted in 
Figure 3. 
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ErbB RTKs also function as signal integrators, cross-regulating different classes of 
membrane receptors [51]. Cross-regulation mechanisms of ErbB receptors can be split in two 
major groups. Either ErbB receptors are phosphorylated by other kinases, which is the case 
for cytokine receptor transactivation, or EGF receptors autophosphorylate as a consequence of 
increased kinase activity due to ligand binding. Ligands availability in these situations is 
provided by metalloproteinase-mediated cleavage of an EGF-like pro-ligand. This second 
mechanism is observed with G protein-coupled receptor (GPCR) agonists as well as by Wnt 
proteins binding to frizzled (Fz) receptors, stimulating EGFR activity and activating the 
MAPK cascade [49]. Cross-regulation of cytokine receptors represents another mechanism 
for controlling and enhancing tumor cell proliferation. Cytokine receptors lack kinase activity 
and associate with Janus tyrosine kinases (Jak) to transduce signals. As an example, activation 
of the growth hormone (GH) receptor activates Jak2 which phosphorylates a tyrosine residue 
in the cytoplasmic domain of ErbB1 leading to Grb2 association and stimulation of the 
MAPK pathway. But RTKs and cytokine receptors can also negatively regulate each other as 
demonstrated on the inhibiting effect of EGF on prolactin (Prl) receptor signaling in the 
mammary gland. Hynes et al. have found that continuous EGFR activation in mammary cells 
inhibits Prl-induced Jak2 activation and therefore suppresses the cells in responding to 
prolactin. ErbB2 and Prl receptor cross-regulation has also been observed. It was recently 
shown in an ErbB2 overexpressing breast tumor cell line that Prl-mediated activation of Jak2 
led to an enhancement of ErbB2 tyrosine phosphorylation [51].  
 
3.3.3 Mutations in ErbB2 
 
Originally two different unrelated mutations were found in Neu, the rat ErbB2 homologue, 
each leading to the onset of transformation. The oncogenic variant of Neu was called NeuT 
[46]. It was Bargmann et al. [52] who first found a single point mutation in the 
transmembrane domain of Neu in chemically induced rat neuroectodermal tumors. These 
findings demonstrated that alterations in the transmembrane segment of rat neu may also have 
profound effects on its biologic activity and transforming ability. The single-point mutation 
(GTG to GAG) results in the valine to glutamic acid amino acid substitution at position 664 in 
the transmembrane domain of the receptor. This point mutation apparently mimics ligand 
induction of receptor activation and results in the activation of the receptor tyrosine kinase 
with constitutive receptor dimerization. The described mutation is the only difference found 
between the oncogenic and proto-oncogenic forms of neu. Later, in tumors from transgenic 
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MMTV/Neu mice, a deletion was found in the extracellular region of Neu, resulting in a 
constitutively activated receptor capable of transforming Rat-1 fibroblasts.  
V-ErbB, originally identified as one of the oncogenes carried by avian erythroblastosis 
virus was shown to encode a homologue of the human EGF receptor [49]. In human cancers, 
activation of wild-type ErbB2 occurs through overexpression, generally due to genomic 
amplification of the ErbB-2 proto-oncogene [8]. It is speculated that high levels of the wild-
type receptor might promote spontaneous homodimerization, thus causing constitutive ErbB2 
activation and signaling [49]. At that time, no activating point mutations of ErbB2, similar to 
what has been described for NeuT, had been found in human tumors [53-55].  
Recently somatic mutations in the kinase domain of human ErbB2 have been 
identified in a small subset of primary lung tumors (NSCLCs) [56]. IHC staining for ErbB2 
revealed no differences between tumors with or without ErbB2 mutations, leading to the 
presumption that overexpression probably does not accompany the mutation [56]. Further 
mutations in the human ErbB2 kinase domain have been detected in gastric, colorectal and 
breast carcinomas by Lee et al. [57]. Again, the mutations were detected with a frequency of 
below 5% of the analyzed cases. Lee et al. identified the two amino acids L755 and V777 to 
be affected in the frequently mutated sites. No ErbB2 amplification was detected in cancers 
with ErbB2 mutations, matching the previous findings in the lung tumors [56,57]. To date it is 
still unknown how these mutations influence ErbB2 activity [16,57]. Apparently, with Neu 
both mutation and overexpression result in stabilization of receptor dimers, which are 
essential for maintaining the tyrosine kinase in its active state. 
Based on the observation that deletion of the whole non-catalytic C-terminal tail of 
ErbB2 abrogated its oncogenic function, the five autophosphorylation sites contained in the 
C-terminal part have been examined. It has been shown that oncogenicity is conferred due to 
a single autophosphorylation site, the most C-terminal tyrosine Y1248. The Y1248 
phosphoresidue of ErbB2 alone regulates the association of SHC with ErbB2. These results 
indicate that the multiplicity of autophosphorylation sites on a receptor tyrosine kinase is not 
essential for transformability. Oncogenic activation of Neu appears to utilize the same 
biochemical pathway, but the ligand-induced initiation event is replaced by the point mutation 
mentioned above [58]. Overexpression of ErbB2 has been shown to occur in a significant 
portion of breast, ovarian, bladder, gastric, and other human malignancies [49]. 
Although a point mutation corresponding to that found in the neu oncogene has not 
been found in the HER2 gene in human tumors, a polymorphism at codon 655 (encodes either 
isoleucine (Ile; ATC) or valine (Val;GTC)) in the transmembrane domain of human ErbB2 
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has been reported in healthy individuals as well as in neuroectodermal tumors. Xie et al. could 
correlate this polymorphism with a decreased risk to develop breast cancer in a population-
based study in Chinese women. Whether the polymorphic ErbB2 proteins differ in their 
ability to transform cells and/or have different tyrosine kinase activities has not been 
determined [59]. 
 
3.3.4 The alterations in ErbB receptor dimerization in cancer cells  
 
Although ErbB2 homodimers alone may contribute to malignancy, a number of observations 
suggest that ErbB2 does indeed cooperate with other ErbB receptors during tumor 
development. Many human tumors that contain ErbB2 also exhibit autocrine stimulation of 
EGFR via expression of one of its numerous ligands [45]. Seton-Rogers et al. describe that 
homodimerization of either EGFR or ErbB2 alone cannot induce cell migration. Induction of 
migration in response to ErbB2 and TGFβ requires secretion of at least one EGFR ligand. It is 
possible that endogenous EGFR ligands stimulate migration through induction of 
heterodimers of EGFR with other ErbB family members, whereas homodimers do not induce 
a migratory response [60]. Heterodimerization and/or transactivation between ErbB2 and 
EGFR results in a high-affinity receptor for EGFR ligands like EGF or TGFα. Elevated 
expression of both receptors can be detected in primary human breast cancers. These 
observations suggest that these two closely related RTKs may collaborate in mammary 
tumorigenesis [61]. The association of frequent co-expression of both ErbB2 and ErbB3 
transcripts, as detected in human breast tumors has been also observed in Cardiff’s ErbB2 
transgenic MMTV mice [48]. If ErbB2 phosphorylation is suppressed without suppressing 
dimerization with ErbB3, generally considered the most active heterodimer with regard to in 
vitro growth and transformation, signaling may continue [62,63]. In a murine hematopoietic 
progenitor cell line, Pinkas-Kramarski et al. [63] found that ErbB3 is devoid of any biological 
activity but both ErbB1 and ErbB2 can reconstitute its extremely potent mitogenic activity. 
They could show that heterodimers amongst ErbB1-3 are more potent than the respective 
homodimers, and ErbB3-containing complexes, especially the ErbB2/ErbB3 heterodimer, are 
more active than ErbB1 complexes. Pinkas-Kramarski et al. propose the following hierarchy 
of receptor crosstalk: ErbB2/ErbB3 > ErbBl/ErbB2 > ErbBl/ErbB1 > ErbB1/ErbB3 [63] (see 
also Fig. 4). 
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Fig. 4. Schematic illustration of various combinations of ErbB proteins and their respective proliferative potentials. 
The ligands depicted are: E = EGF; N = NRG1, mAb = a monoclonal antibody that binds to ErbB2. The crosses in 
the cytoplasmic domain of ErbB3 indicate an impaired tyrosine kinase activity. At the time of publication the fourth 
ErbB family member (ErbB4) was still unknown. The proliferation index represents the signal obtained in MIT 
assays after a 48 h-long incubation with saturating concentrations of the corresponding ligand, and it is calculated 
relative to the effect of IL-3. Note that heterodimers of ErbBl and ErbB3 can be activated by either ligand (arrows). 
Figure taken from Pinkas-Kramarski et al. [63]. 
 
 
Homodimeric receptor combinations are less mitogenic and transforming than the 
corresponding heterodimeric combinations, and ErbB2-containing heterodimers are the most 
potent complexes. The NRG-induced ErbB2–ErbB3 heterodimer is the most transforming and 
mitogenic receptor complex [7]. Indeed, the fact that ErbB2 does not constitutively display 
maximal activity when expressed in cells, and that it must be overexpressed to quite high 
levels to cause cell transformation, suggests that ErbB2 homodimerization is rather weak. 
Antibodies with different epitopes could potentially change the orientation of ErbB2 
homodimers or heterodimers to one another, substantially changing phosphorylation and 
downstream signaling. Antibodies to ErbB2 are predicted to change the rotational 
conformation of dimers relative to one another and in this way either inhibit or activate ErbB2 
signaling. If antibodies suppress intramolecular phosphorylation without down-regulating 
membrane localization, effective suppression of ERK signaling may not occur [62]. 
 
 
Approximately 30% of human breast tumors overexpress EGFR and this overexpression is 
correlated with a loss of estrogen responsiveness and a poorer prognosis. Much evidence 
suggests that EGFR is involved in later stages of human breast cancer and may play a role in 
the metastatic process [64]. 
However, the two main signaling cascades are the PI3K/Akt and the ras-Raf-MAPK 
pathway. How they can be deregulated in ErbB2 overexpressing tumor cells is described in 
more detail in the following two chapters. 
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3.3.5 The PI3K/Akt pathway under ErbB2 overexpression 
 
PI3K is strongly activated in ErbB2 initiated tumor cell 
lines derived from transgenic mice and a specific PI3K 
inhibitor is able to block anchorage independent growth 
in the same model. These findings of Amundadottir et 
al. [65] demonstrate that ErbB2 mediated tumor cells 
require PI3K for the transformed phenotype. ErbB2 
activates the PI3K/Akt pathway and confers resistance 
to apoptosis induced by tumor necrosis factor. Akt 
detaches from the inner surface of the plasma 
membrane, where it is initially activated, and relocalizes 
to the nucleus within 30 min of activation by growth 
factors. ErbB2-mediated cell growth requires the 
activation of Akt which localizes p21
Cip1/WAF1
 to the 
cytoplasm. p21
Cip1/WAF1
 is a member of the cyclin-
dependent kinase inhibitors and is expressed during 
cellular senescence. However, the cell-growth-
inhibiting activity of p21
Cip1/WAF1 
is strongly correlated 
with its nuclear localization. p21
Cip1/WAF1
 can also be 
localized in the cytoplasm where it has an important 
role in protecting cells against apoptosis. It has been 
shown that cytoplasmic p21
Cip1/WAF1
 inhibits the MAPK 
cascade via ASK1 and therefore results in resistance to 
apoptosis. In this sense, overexpression of ErbB2 may 
enhance cell proliferation by inducing cytoplasmic localization of p21
Cip1/WAF1
 which in turn 
inhibits MAPK signaling [66]. Akt kinase activity is frequently increased in breast cancers, 
where it is associated with poor prognosis and resistance to tamoxifen and radiotherapy. Akt 
may play important roles in ErbB2-mediated mammary tumorigenesis, because ErbB2 
possesses seven consensus docking sites for PI3K and can therefore transduce multiple 
signals through the PI3K/Akt pathway. A simplified version of the PI3K/Akt pathway is 
depicted in Figure 5. Hutchinson et al. [48] have investigated the importance of Akt activation 
in ErbB2 mammary tumor progression using a bitransgenic mouse model designed to co-
express activated Akt and activated ErbB2 each under an MMTV promoter. Concomitant 
P P
EGFR/ErbB2
Src
PI3K
Akt
p21
p21
Cell growth, AIG, 
resistance to apoptosis
Fig. 5. The PI3K/Akt pathway
activated through ErbB2. A 
simplified scheme.
23 
activation of Akt accelerated ErbB2 mediated mammary tumor progression which correlated 
with enhanced cellular proliferation and elevated Cyclin D1 levels. On the contrary, these 
bitransgenic tumors showed lower levels of invasion and a significantly lower metastatic 
potential [48].  
It has been argued that activation of the PI3K/Akt/mTOR pathway by ErbB2 
overexpression predicts tumor progression in breast cancer [67]. Phosphorylation of Akt and 
mTOR (mammalian target of rapamycin) increases progressively from normal breast 
epithelium to hyperplasia and abnormal hyperplasia to tumor invasion [67]. The upstream 
molecules PI3K/Akt activate mTOR resulting in the initiation of protein translation. 
Phosphorylated Akt and mTOR were positively associated with ErbB2 overexpression in vivo 
as well as in vitro [67]. Signaling from the proto-oncogene ErbB2 has been shown to inhibit 
the adhesive function of the collagen receptor integrin α2β1 in human mammary epithelial 
cells. This anti-adhesive effect is mediated by the MAP ERK kinase 1/2 (MEK 1/2) and 
PI3K/Akt (protein kinase B, PKB) pathways. Hedjazifar et al. [68] could demonstrate that 
both pathways mediate suppression of matrix adhesion in a parallel fashion by causing the 
extracellular domain of the β1 integrin subunit to adopt an inactive conformation. In addition 
the PI3K/mTOR pathway was recognized as mediator of integrin inhibition but without 
causing conformational inactivation [68]. 
 
3.3.6 The MAPK pathway under ErbB2 overexpression 
 
Oncogenicity of ErbB2 is almost fully dependent on an active Y1248, signaling via the Ras-
MAPK (ERK) pathway. Mutation or deletion of tyrosine Y1248 in the non-catalytic C-
terminal of ErbB2 abrogates downstream ERK activation, and implicate the MAP kinase 
pathway in transduction of the oncogenic signal of ErbB2 [58]. 
ErbB2 specifically activates the ERK/MAPK pathway, and relies on this pathway to 
mediate transformation and to maintain the transformed phenotype (see Fig. 6). An inhibitor 
of MAPK kinase, the upstream activator of ERK, blocks phenotypic transformation by ErbB2 
in the same model, confirming the importance in ERK signaling for transformation [65]. 
MAPKs are differentially activated by growth factors, hormones and cytokines. In addition, 
MAPK cascades may be activated by cellular stresses including irradiation, heat shock, 
osmotic imbalance, DNA damage, and bacterial products such as lipopolysaccharide. 
Activation of MAPKs in response to these stimuli controls gene expression, metabolism, 
cytoskeletal functions and other more complex cellular regulatory events, such as 
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mitogenesis, differentiation, survival and 
migration [69]. Although other signal 
transduction pathways are clearly important in 
ErbB2-mediated transformation, activation of 
ERK is a consistent downstream consequence of 
ErbB2 expression and is generally considered the 
principal driver of cell proliferation. Seton-
Rogers et al. [60] were using a model of 
chimeras of ErbB1 and ErbB2 which were 
inducibly activated by means of 
homodimerization.  In the absence of EGF, 
dimerization of either receptor per se was 
sufficient to promote proliferation. Both 
receptors induced activation of ERK and were 
competent to bind SHC and GRB2, a pattern 
consistent with their wild type counterparts. 
Activated ErbB2 alone was not able to induce 
transformation of human mammary epithelial 
cells (MCF10A) in terms of anchorage 
independency, invasion and migration. MCF10A 
cells were grown in a three-dimensional culture 
imitating acini (Matrigel, also described in 
chapter 3.3.9). Coactivation of ErbB2 and TGFβ 
signaling pathways induced invasive activity of MCF10A cells. ERK activation was required 
for the observed synergy between ErbB2 and TGFβ, but was not sufficient to induce 
migration or invasion, except when co-expressed with TGFβ [60]. 
Endogenous anti-HER2 antibodies induced in human by HER2 peptide vaccines are 
capable of blocking HER2 phosphorylation on tyrosine Y1248 and consequently blocking 
signaling through the MAP kinase ERK1/2 [62]. The suppression of ERK activity through 
HER2 antibodies [62] has another interesting implication since suppression of ERK in HER2-
expressing cells restores sensitivity to tamoxifen. MAPK has been shown to phosphorylate 
Ser-118 in the estrogen receptor (ER), leading to ligand-independent ER activation with loss 
of the inhibitory effect of tamoxifen. Kurokawa et al. [70] could demonstrate that interruption 
of the MAPK cascade enhanced the inhibitory effect of tamoxifen on both ER-mediated 
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Fig. 6. The MAPK pathway activated
through ErbB2. A simplified scheme.
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transcription in vitro and on tumor cell proliferation in vitro and in vivo. These findings were 
consistant in three different attempts of blocking the MAPK pathway, with either small 
molecule inhibitors of the HER2 kinase, inhibitors of the MAP kinase kinases (MEK-1/2) or 
via a dominant-negative mutant of MAPK [70]. Extensive research has documented the role 
of MAPK in vitro and in animal models in breast cancer, though data are inconclusive and 
sometimes contradictory with respect to proliferation, anoikis (apoptosis induced by loss of 
cell adhesion) and the association between MAPK, estrogens, and HER2. In therapy-related 
models, ErbB receptor inhibition combined with Gemcitabine results in elevated p38 and 
reduced ERK and AKT with ensuing apoptosis, but both ERK and p38 are elevated prior to 
paclitaxel-induced apoptosis. The expression, activation status, and the clinical role of p38 
and JNK in breast cancer are unknown at present. p38 activation in breast carcinoma 
effusions is inversely linked to c-erbB2 expression, with no apparent relationship between this 
tyrosine kinase receptor and p-ERK or p-JNK. Davidson et al. [50] have previously shown 
that expression and phosphorylation of all three MAPK members is associated with clinical 
parameters of better outcome and better survival in ovarian carcinoma patients with effusions. 
These data have been reproduced in primary ovarian carcinomas. Davidson et al. have found a 
correlation between higher p38 activation ratio and poor disease-free survival and overall 
survival (OS). Notably, expression and activation of ERK did not correlate with any of the 
clinical parameters of aggressiveness or with survival in this cohort. Data regarding the role 
of phospho-ERK expression in primary breast cancer are contradictory [50].  
 
3.3.7 The PKC pathway under ErbB2 overexpression 
 
Protein kinase C (PKC) is a family of serine/threonine kinases that are involved in the 
signaling pathways that regulate cell proliferation, differentiation, apoptosis, motility and 
adhesion. The α-isozyme of PKC, PKCα, is widely expressed in various tissues. PKCα 
expression and activity have been found to be elevated in human breast cancer cells and are 
associated with an increased invasive or metastatic potential. In the classic model of PKC 
activation by receptor tyrosine kinases, ErbB2 (among other RTKs) phosphorylates and 
associates with phospholipase-γ (PLCγ), which may lead to the activation of PKCα (see Fig. 
7). Tan et al. [71] showed that Src is co-immunoprecipitated with PKCα and that Src kinase 
activity contributes to PKCα activation by ErbB2 in human breast cancer cells. 
Overexpression or activation of ErbB2 upregulates and activates PKCα through Src, 
promoting breast cancer cell invasion. Downregulation of ErbB2 decreased expression and 
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activity of PKCα. These findings have been made in vitro as well as in vivo and suggest that 
Src kinase is another important regulator of PKCα activation in breast cancer cells [71]. The 
human c-Src proto-oncogene encodes an intracellular tyrosine kinase, pp60c-Src. c-Src was 
originally identified as a homologue of the transforming gene of the Rous sarcoma virus and 
is the prototype of a family of highly conserved genes that includes yes, fyn, fgr, lyn, lck, hck, 
blk, and yrk. Src family 
proteins have been 
implicated in many signal 
transduction pathways and 
in a wide variety of 
cellular functions. 
Activation of Src kinase 
has been linked to the 
development of many 
human neoplasias, 
especially those of the 
colon, breast, lung, and 
pancreas [72].  Src binds 
to tyrosine phosphorylated 
ErbB2 and is activated in 
ErbB2-overexpressing 
cancer cells [73]. A 
striking feature of c-Src 
association with the 
EGFR family is that it is 
restricted to the ErbB-2 
receptor and cannot 
directly interact with the 
closely related EGFR [74]. Overexpression of c-Src alone is insufficient to transform murine 
fibroblasts in culture or to sustain tumor growth in intact animals. Studies in transgenic mice 
have demonstrated that c-Src is necessary for induction of mammary tumors by the 
polyomavirus middle T oncogene [64]. There appear to be two prominent roles of c-Src in 
this regard. One is to modulate receptor function by augmenting signals immediately 
downstream of the receptors and by regulating endocytosis, and the other is to affect 
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Fig. 7. The PKCα and Src signaling activated through ErbB2. A 
simplified scheme.
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morphogenetic remodeling of the cell by phosphorylating proteins that associate with the 
actin cytoskeleton. Previous results suggest that an ErbB2–c-Src complex may play an 
important role in heregulin-stimulated anchorage-independent growth and antiapoptotic or 
survival mechanisms, but have less of an effect on anchorage-dependent growth [64]. Kim et 
al. [75] could show that c-Src interacts with a tyrosine residue on ErbB2 that is distinct from 
the five major autophosphorylation sites. They demonstrated that c-Src associates specifically 
with the kinase domain of ErbB2. Further investigation revealed that the ErbB2-dependent 
activation of c-Src results in a disruption of epithelial cell–cell contacts leading to cell 
dispersal and loss of cell polarity. The experiments were conducted on chimeric EGFR 
competent in c-Src recruitment. In contrast to the EGFR expressing normal epithelial kidney 
cells (MDCK), the chimera expressing cells exhibited a dramatic scattering and invasion 
phenotype in response to EGF. These observations correlated with the relocalization of 
phospho-MAPK to the cytoplasmic membrane and were dependent on a functional 
MEK/MAP kinase cascade [75]. Tan et al. [72] showed that activation of ErbB2 can lead to 
increased Src protein synthesis, through activation of the Akt/mTOR pathway, and decreased 
Src protein degradation through the inhibition of the calpain protease. These two novel 
mechanisms result in Src protein upregulation and activation, which play critical roles in 
ErbB2-mediated breast cancer invasion and metastasis. Furthermore, inhibition of Src activity 
by a Src-specific inhibitor, PP2, or a Src dominant-negative mutant dramatically reduced the 
oncogenic potential of ErbB2-mediated cancer as determined on cell invasion and metastasis. 
Tan et al. [72] could report the first experimental evidence that the higher metastatic potential 
of ErbB2-overexpressing breast cancer cells is mediated through and even requires increased 
Src activities. 
 
3.3.8 The internalization of ErbB2 
 
The principal process that turns off signaling by the ErbB network is ligand-mediated receptor 
endocytosis, and the kinetics of this process also depend heavily on receptor composition. On 
ligand binding, ErbB1 molecules cluster over clathrin-coated regions of the plasma 
membrane, which invaginate to form endocytic vesicles. These mature to early and late 
endosomes, while gradually decreasing their internal pH and accumulating hydrolytic 
enzymes that lead to receptor degradation. Importantly, the other three ErbB proteins are 
endocytosis impaired and are more often recycled back to the cell surface. Sorting to 
degradation is determined by the composition of the dimer: ErbB1 homodimers are targeted 
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primarily to the lysosome; ErbB3 molecules are constitutively recycled; and 
heterodimerization with ErbB2 decreases the rate of endocytosis and increases recycling of its 
partners [7]. Sorting in the early endosome seems to depend on the pH stability of the ligand-
receptor interaction. EGF interaction is relatively pH resistant and targets EGFR to lysosomes 
whereas transforming growth factor α (TGFα) readily dissociates from the receptor at 
endosomal pH, resulting in receptor recycling. Subsequent rerouting of the receptor to the 
plasma membrane may, therefore, play a major role in signal potentiation [45]. 
Cbl protein, an E3 ubiquitin ligase that promotes ubiquitinylation and degradation of 
activated receptors plays a critical role in antibody-induced HER2 downregulation, as in the 
case of Trastuzumab. Antibody stimulation induces HER2 receptor activation and 
phosphorylation in tyrosine 1112 known to be responsible for the recruitment of Cbl. Upon 
binding, Cbl catalyses the transfer of ubiquitin molecules to HER2. Ubiquitinylated receptor–
Cbl complexes are endocytosed by clathrin-coated pits, fuse into early endosomes and move 
to lysosomes where the receptor is destroyed. In the absence of such antibodies, 
phosphorylated HER2 only weakly associates with Cbl and it is thus resistant to Cbl-induced 
downregulation. HER2 heterodimerization with other members of the EGFR family prevents 
HER2/Cbl association and avoids the lysosomal fate, favouring recycling, and this accounts 
for HER2 heterodimers enhanced signaling potency. The initiation steps of HER2 endocytosis 
could be attributed to the autocrine production of TGFα, a mechanism known for governing 
EGFR downregulation. Valabrega et al. [18] show that metastatic cells examined after 
Trastuzumab treatment acquire the ability to express TGFα. Tumor cells often produce TGFα 
that acts either in an autocrine or in a paracrine manner. TGFα has been found to have 
synergistic interaction with Neu regarding the formation of multifocal mammary tumors in 
the mammary epithelium of bitransgenic mice co-expressing TGFα and Neu. The 
development of the tumors was correlated with the tyrosine phosphorylation of Neu and the 
recruitment of c-Src to the Neu complex. A probable biochemical explanation for this 
observation is that TGFα activates Neu-associated tyrosine kinase activity by 
transphosphorylation through the activated EGFR [61]. 
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3.3.9 The HER2-transformed phenotype of the mammary gland 
 
Human mammary epithelial cells overexpressing HER2 have been shown to undergo two 
major changes in cellular behaviour with high relevance to tumorigenesis; firstly, the 
epithelial-to-mesenchymal transition (EMT), and secondly, anchorage independent growth 
(AIG). In EMT, the epithelial characteristics of the cells, such as cell polarity, the presence of 
adherens junctions, tight junctions and desmosomes, and expression of many epithelium-
specific proteins, are lost and replaced with a more or less fibroblastic phenotype [76] 
characterized by a change to spindle-like cell morphology and a gain of mesenchymal 
markers [60]. AIG is usually detected by the classical parameter of growth capacity in soft 
agar. In a model of mammary epithelial cells overexpressing a chimaeric NeuT, Jenndahl et 
al. [76] support the finding that EMT is a critical phenotypic change required for AIG in 
ErbB2 signaling. Activated ErbB2-induced EMT has been shown to be mediated and 
dependent on c-Src in normal epithelial kidney cells (MDCK) [75]. When HER2 is 
overexpressed in an infected human breast cancer cell line (MDA-MB-231), it appears to 
synergize with the TGFβ pathway to potentiate pro-invasion, angiogenesis, and EMT [77]. 
ErbB receptor heterodimer signaling is known to stimulate cell motility through induction of 
PLCγ, activating either IP3, DAG and calcium or PKCα [78]. In HER2-overexpressing cells, 
PKCα induction is potentiated through Src [71], as described in chapter 3.3.7. Dittmar et al. 
[78] have shown that ErbB2 initiates the cell migration program by modulating the time 
course of PLCγ activation and that this effect is dominantly regulated by the EGFR 
transphosphorylated tyrosine residue 1248 of ErbB2, upon EGF interaction. Furthermore, 
EGFR signaling either in homo- or heterodimer configuration has revealed to be crucial for 
PLCγ activation [78]. 
An in vitro model of the in vivo architecture of mammary acinar structures is represented 
by human mammary epithelial cells forming growth-arrested acinar structures when cultured 
within a three-dimensional matrix rich in laminin and collagen IV suspension (Matrigel). 
Muthuswamy et al. [5] investigated the effect of overexpressed chimaeric ErbB2 in such a 
model system and found evidence that simple overexpression of ErbB2 is not enough to 
induce invasive phenotypes. The chimaeric ErbB receptors consist of the extracellular and 
transmembrane domains of the nerve growth factor receptor and ErbB1 or ErbB2 cytoplasmic 
domains linked to the synthetic-ligand-binding domain from FK506-binding protein (FKBP). 
The chimaeric ErbB receptors can be dimerized with the bivalent FKBP ligand AP1510. 
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Treatment with AP1510 induced tyrosine phosphorylation of the chimaeras but not of 
endogenous ErbBs. EGF stimulation, required for the proliferation of the cell model, did 
exclusively activate the endogenous ErbBs and not the chimaeras. Activation of ErbB2, but 
not ErbB1, homodimers has led to altered mammary acini structures that share properties with 
ductal carcinoma in situ, such as loss of proliferative suppression and repopulation of lumen. 
ErbB2 activation also disrupted tight junctions and the cell polarity of polarized epithelial 
cells. Interestingly, the epithelial cells did not invade the basement membrane or display 
anchorage independence. Thus, ErbB2 activation did not induce a fully transformed 
phenotype. The findings suggest that activation of ErbB2 can induce early stages of mammary 
carcinogenesis but is not sufficient to induce invasive phenotypes. It has been suggested that 
additional genetic or epigenetic events are needed for mammary epithelial cells to acquire 
invasive properties [5]. These findings are supported by Seton-Rogers et al. [60] observing 
ErbB2 activation in similar three-dimensional cell cultures imitating human acini and using 
Muthuswamys’ chimaeric ErbB receptors.  
Complex organisms have evolved cellular mechanisms to suppress the proliferation of 
cells at risk for oncogenic transformation. The two main mechanisms are apoptosis or 
programmed cell death, and cellular senescence. Cellular senescence is an irreversible growth 
arrest and a major failsafe that cells must overcome to reach the malignant phenotype. This 
mechanism was first discovered to occur in normal cells after a limited number of cell 
divisions, driven by telomere shortening and was termed ‘replicative senescence’. Meanwhile 
stimuli having little or no impact on telomeres were shown to induce senescence in normal 
cells, and the term for the mechanism was broadened to ‘cellular senescence’. These stimuli 
include DNA damage through oxidation, chromatin remodelling and strong mitogenic signals 
such as the activated forms of Ras, Raf or MEK. These stimuli induce senescence after only a 
few cell divisions. Cellular senescence is controlled by several tumor-suppressor genes such 
as p53 and pRB, in vitro as well as in vivo. Cells derived from p53 knockout mice failed to 
senesce in response to such stimuli and the animals developed cancer at an early age. 
Furthermore, a genetic manipulation that causes premature senescence of mammary epithelial 
cells suppresses the development of breast cancer in mice subsequently exposed to the mouse 
mammary tumor virus [79]. Cellular senescence causes many changes in gene expression, 
only some of which are involved in the growth arrest. Upon senescence, human fibroblasts 
also become resistant to apoptosis and overexpress genes encoding secreted proteins such as 
growth factors which in turn stimulate neighbouring cells to grow. Growth stimulation was 
observed only with preneoplastic, but not normal, human epithelial cells. One hypothesis for 
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these opposing effects is that cellular senescence is antagonistically pleiotropic, contributing 
to age-related tumorigenesis [79]. Expression of tumor-promoting factors by senescent cells is 
mediated in part by senescence-associated cyclin-dependent kinase inhibitors such as 
p21
Cip1/WAF1
. Senescent cells show characteristic changes in morphology, such as enlarged and 
flattened cell shape and increased granularity. Tumor cells have not lost the ability to senesce, 
but can be even induced to undergo senescence by genetic modifications, chemotherapy, 
radiation, retinoids or TGFβ. Treatment-induced senescence was shown to be one of the key 
determinants of tumor response to therapy in vitro and in vivo [80]. Senescence has also been 
described as ‘living cell death’ because cells maintain the integrity of their plasma membranes 
[81], remain metabolically and synthetically active, but cannot divide even if stimulated with 
mitogens [80]. Senescence is accompanied by the induction of senescence-associated β-
galactosidase (SA-β-gal) activity, which is commonly used as a marker for senescence [81]. 
Trost et al. [82] have found that tightly regulated overexpression of the oncogenic rat 
homologue NeuT in human breast carcinoma cells does not stimulate proliferation but 
provokes premature senescence, accompanied by induction of p21
Cip1/WAF1
, SA-β-gal and the 
typical morphologic alterations. The same behaviour was observed with retrovirus-mediated 
overexpression of NeuT in low-passage murine embryonic fibroblasts. A tetracycline-
regulated NeuT expression system was used by Trost et al. [82], which results in p21
Cip1/WAF1
 
localization to the nucleus in the growth arrested cells. Previous studies using constitutively 
overexpressing cell lines observed localization of p21
Cip1/WAF1
 to the cytoplasm where it 
enhanced cell proliferation [66] (p21
Cip1/WAF1 
is described in more detail in chapter 3.3.7). 
Furthermore, specific inhibition of the MAP kinase p38, but not ERK1/2 or PI3K, reversed 
the phenotypic alterations and functional inactivation of p21
Cip1/WAF1
 prevented growth arrest 
and the senescent phenotype. It has been documented that the biological outcomes of 
oncogenic signaling via the Ras-Raf-MEK-ERK (MAPK) cascade critically depend on the 
strength and duration of the signal. Thus, the induction of senescence in the regulated 
expression system, but not in the constitutively overexpression system, could be due to a 
similar effect. However, Trost et al. [82] observed the features of senescence after 2-7 days of 
NeuT induction. The authors speculate that subcellular relocalization of p21
Cip1/WAF1
 to the 
cytoplasm due to Akt may be an essential secondary step to escape cellular senescence [82]. 
Mammary gland functional differentiation occurs with distinct morphological and 
molecular changes of the epithelial cells and allows for the production and secretion of milk. 
Thus, the secretory alveolar cells represent the final cellular state of the life-spanning 
multistep differentiation process within the mammary gland. These differentiation steps 
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taking place during pregnancy and lactation are defined and characterized by the sequential 
activation of genes encoding the milk proteins such as β-casein, whey acidic protein (WAP) 
and α-lactalbumin. Mammary gland development in response to lactogenic hormones in vitro 
was known to be accompanied by a distinct morphological change of the cells forming 
structures called domes. Zucchi et al. [83] have correlated the dome formation in vitro with 
differentiation processes occurring in the mammary gland at pregnancy. Dome formation was 
shown to be inducible by the lactogenic hormones hydrocortisone (HC) and prolactin (PRL) 
and could be paralleled with the expression of the milk protein β-casein, which is a specific 
marker of the initial stage of mammary gland functional differentiation [83]. 
Hynes et al. [84] have reported that induction of β-casein in HC11 mouse mammary 
epithelial cells by the lactogenic hormones insulin, prolactin and the glucocorticoid 
dexamethasone can be suppressed by EGFR activation but not oncogenic human ErbB2 or 
NeuT signaling. In order to investigate the exact function of ErbB2 during normal breast 
development, Jones and Stern [85] inactivated endogenous ErbB2 signaling through 
expression of a dominant negative truncated ErbB2 transgene during mouse mammary gland 
development. They found that normal ErbB2 signaling is required for the terminal stages of 
lobuloalveolar development and lactation as measured by the observation of inhibited alveolar 
growth and non-secreting lobuloalveoli under transgene expression [85]. The influence of 
oncogenic rat NeuT on mouse mammary gland development has also been studied in 
transgenic mice overexpressing NeuT. Expression is controlled by the MMTV-LTR promoter, 
leading to an elevated level of expression during late pregnancy and throughout lactation. 
Transgene expression was assessed at lactation and early involution and revealed to be 
restricted to morphologically transformed cells whereas no endogenous mouse c-erbB2 was 
detected in wild-type glands. NeuT expressing tumor cells completely failed to express the 
milk proteins β-casein and WAP at lactation or during involution [1]. 
Senescence can be induced in primary or early passage cells by MEK activation and 
reversed by blocking p38, but not ERK1/2 or PI3K. Constitutive overexpression of NeuT is 
critical for overcoming senescence, strength and duration of signaling play a pivotal role. 
With NeuT overexpression, EMT via Src is required for AIG. Cell motility is mediated 
through Y1248-activated PLCγ (EGFR involvement crucial) and PKCα (potentiated through 
Src). ErbB2 and not ErbB1 homodimer signaling is responsible for loss of proliferative 
suppression and repopulation of lumen, but per se is unable to induce invasive behaviour. 
Normal ErbB2 signaling is required for the development of the mammary gland, which is 
accompanied in vitro by dome formation, inducible by HC and PRL and paralleled by β-
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casein expression. EGFR, but not overexpressed mutated HER2 or NeuT, suppresses β-casein 
production. NeuT expression in tumor cells blocks the differentiation of the gland. Again, an 
expression-level dependent function can be attributed to ErbB2 receptors in mammary gland 
development. 
In order to learn about the influence of ErbB2 on normal, polarized mammary epithelial 
cells, we decided to study the differentiation in vitro of the Clone 31 mouse mammary 
epithelial cells in culture, using retroviral constructs to infect with either human or murine 
ErbB2 or the oncogenic rat NeuT.  
 
4 Materials and Methods 
4.1 The animal work 
4.1.1 The animal model 
 
Vaccination studies were performed in female FVB inbred mice originally obtained from 
Charles River, Germany. The mice have the MHC status H-2q. All experiments have been 
conducted in accordance with the Swiss Tierschutzverordnung. The transplanted tumors grew 
until the size reached the termination criterion of 200 mm
2
, when the mice were sacrificed. 
 
4.1.2 Surgery of the mice 
 
For injections into the mammary gland and the spleen mice were anesthetized with a liquid 
triple narcotics (see Table 1) injected i.p. Animals were kept under anaesthesia for maximal 
15 minutes. Narcosis was reversed with a subcutaneous injection of an antidote mixture 
(Table 1). Access to the mammary gland was gained by fixing the anesthetized animal on the 
back with tape bands and incising the skin in the region of the inguinal right mammary gland. 
Injections of Met-1 cells were done directly into the fat pad of the mammary gland where the 
subsequent formation of a bulge indicated a well-targeted application.  
For transplantation of tumor tissue fragments, the fat pad of the inguinal mammary gland 
was incised with sharp forceps in order to form a pocket in which the tissue fragment was 
then enveloped. 
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Table 1. Composition of anaesthetics and antidote 
Narcotics Corresponding antidotes 
 Conc. in 
mixture 
[mg/ml] 
 
Dosage per FVB 
mouse (~20g) in 
50ul mixture, in µg 
 Conc. in 
mixture 
[mg/ml] 
Dosage per FVB 
mouse (~20g) in 
80ul mixture, in µg 
Medetomidin 
HCl 1mg/ml 
(Domitor
®
) 
0.25 12.5 Atipamezol 
HCl 5mg/ml 
(Antisedan
®
) 
1 80 
Climazolam 
10mg/ml 
(Climasol
®
) 
2.5 125 Sarmazenil 
1mg/ml 
(Sarmasol
®
) 
0.2 16 
Fentanyl  
0.05mg/ml 
(Fentanyl-Janssen
®
) 
0.025 1.25 Naloxon HCl 
0.4mg/ml 
(Narcan
®
) 
0.24 19 
 
For dissecting the spleen, the mouse was laid on its right side, a 10mm long skin flap 
was cut out and the spleen could then be localized by eye through the peritoneum. Through a 
fine cut in the peritoneum (approx. 4mm) the spleen was gently extracted for about 1cm with 
a flat forceps. The application was performed by inserting the needle along the tongue shaped 
organ and progressively retracting it while injecting, in order to prevent congestion in the 
dense tissue. With this technique the spleen can hold an application volume of 30-50ul. 
The injections into the gastrocnemius muscle were performed in the non-anaesthetized 
animal without dissection of the muscle, except for the injections followed by electroporation. 
In the case of the applications supported by electroporation, the treatment was done under 
narcosis and the muscle was dissected for precise localization of the injection site and to 
ensure conduction of the current. 
Incisions were sewed with non-resorbing Ethilon II 4-0 FS-2 Ethicon Polyamid 6 
monofil suture, Johnson & Johnson.  
Blood samples were taken from the tail by cutting a 1mm piece off the tip [86]. 
Repeated blood retrieval was limited to 4 samples per animal spread over 2 months. For each 
sample 100ul of whole blood was collected in a glass microcapillary and stored overnight at 
4°C in an uncoated centrifuge microtube for coagulation. The sample was then centrifuged 
twice 10 minutes at 13’000 rpm in an Eppendorf microfuge and the serum aliquoted and 
frozen at -20°C.  
 
4.1.3 In vivo electroporation 
 
In order to improve gene transfer in our naked DNA vaccination protocols, we applied in vivo 
electroporation to the spleen and muscle of anaesthetized mice with the kind help of Dr. Amiq 
Gazdhar. Electroporation conditions had been previously optimized by Gazdhar et al. [36] to 
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four pulses (200 V/cm, 20 ms at 1 Hz) using flat plate electrodes. The organ has been 
electroporated immediately after injection of the plasmid DNA at the site of injection (Fig. 8). 
 
               
Fig. 8. Electroporated spleen after injection of 80ug mutHER2 plasmid (A) or 80ug 
pBabepuro vector (B); stained with anti-ErbB2/HER2 antibody (Upstate). 40x 
magnification.
A B
 
 
4.2 The tumor model 
 
Mouse mammary primary tumor cells from the FVB Met 1-line, transgenic for wild type 
PyV-mT [87], were the generous gift of Dr. Robert D. Cardiff (Centre for Comparative 
Medicine, University of California, Davis, USA) and were maintained in vitro and in vivo as 
well. For in vivo studies tumor cells were injected directly into the lower right mammary 
gland of female FVB mice. Cells were administered as suspension in Eagles Dulbecco-
Modified cell culture medium lacking foetal calf serum. The following characteristics have 
been observed in vivo: 
 
Met-1: 
a) Tumor development was reproducible, growth has been observed in 24 out of 25 animals.  
b) Low doses, 10’000 - 25’000 cells develop tumors faster than larger (50’000 cells). 
c) When primary tumors are surgically removed, some regrow at the site, others do not. 
 
Met-1 infected with either mouse c-erbB2 or human ErbB2: 
a) Infection with ErbB2 did not alter the growth rate or morphology of the Met-1 tumor. 
b) With Met-1 mouse pBabe
puro
 ErbB2, 10’000 cells initiated tumors more rapidly than 
30’000 cells but 3’000 cells did not produce 100% tumors. 
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c) With Met-1 human pBabe
puro
 ErbB2, 30’000 cells were found to be above the threshold for 
producing 100% tumors. 
d) The tumors remain transplantable. 
 
Expression of the antigen has been checked by IHC, as shown for c-erbB2 in Figure 9. 
 
              
Fig. 9. Met-1 primary tumor infected with c-erbB2 (A) or pBabepuro vector (B); staining
was done with anti-ErbB2/HER2 antibody (Upstate); 20X magnification.
A B
 
 
4.3 Cell cultures and cell lysates 
 
3T3 FVB fibroblasts were prepared in our laboratory and used at approximately the 50
th
 
passage. These had the MHC status H-2q, so they are syngeneic to the FVB mice used in the 
experiments. The mouse mammary epithelial (31E) and stem cell (30F) lines were established 
from BALB/c mice and characterized by Dr. Ernst Reichmann in our laboratory as described 
previously [88]. Cells were cultured in Eagle’s Dulbecco-Modified medium enriched by 10% 
foetal calf serum (EDM10). Cells prepared for injection in the mice were resuspended in 
serum-free EDM in order to minimize unspecific immunological reactions. The cells used in 
the EGF-stimulation experiments had been deprived of EGF one week before and deprived of 
serum 20-24 hrs prior to stimulation with EGF. Stimulation has been done with 40 ng/ml EGF 
for 0, 2, 5, 15 and 30 min. 
For generation of cell lysates, confluent cells from a 5 cm plate were washed with 
phosphate buffered saline and incubated at 4°C for 10 min in 1 ml of modified RIPA lysis 
buffer (see Appendix B). Following Dounce homogenisation, samples were centrifuged at 
20’000 g for 10 min and the collected supernatant represented the cytosol containing also 
membrane proteins. After determination of protein concentration using the Bradford-based 
Bio-Rad Protein Assay (Bio-Rad Laboratories GmbH, Munich, Germany), the lysates were 
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diluted to 1X SDS-PAGE sample buffer (80mM Tris pH 6.8, 2% SDS, 10% glycerol, 2% 2-
mercaptoethanol and 0.02% bromphenol blue) and boiled for 2 min. Total cell lysates were 
collected by lysing cells directly with 1X SDS-PAGE sample buffer (1 ml for a 10 cm cell 
culture dish) and boiling the lysates for 2 min. 
 
4.4 In Vitro Differentiation Assays, soft agar and Matrigel growth 
assays 
 
In order to induce functional in vitro differentiation of Line 31E mouse mammary epithelial 
cells expressing the various ErbB2 constructs, co-cultures were prepared with Line 30F cells 
as described in Reichmann et al. [88].  After culture for 48 hrs in medium supplemented with 
EGF (10 ng/ml), cells were incubated for 24 hrs in EDM with 3% foetal calf serum,  5 ug/ml 
insulin, 1 ug/ml hydrocortisone and 5 ug/ml ovine prolactin. Thereafter, supernatants were 
discarded and cells lyzed using RIPA lysis buffer (Appendix B) for determination of β-casein 
in Western blots using a specific antibody against mouse β-casein. 
For determination of the electrical resistance across the monolayers of Line 31E cells 
infected with the different ErbB2 constructs, cells were grown to confluence on cellulose 
nitrate filter inserts (diameter 2.2 cm). Resistance measurements were obtained with the 
Millipore (Bedford, MA., USA) Millicell-ERS instrument, essentially a millivolt/ohmmeter 
that provides an alternating voltage source to minimize cell damage. 
Culture in soft agar was performed by mixing gently 50’000 cells in EDM10 at room 
temperature with EDM10/Noble agar at 42°C to give a final concentration of 0.37%. 3 cm 
culture dishes which had been covered with 0.8 ml EDM10 containing 1% Noble agar as a 
hard agar under-layer, were overlayed with 1.5 ml of the cell suspension. Incubation was for 6 
days at 37°C in a conventional CO2 incubator. Culture in Matrigel (Growth factor depleted; 
Collaborative Research) was performed according to the manufacturers instructions by 
diluting an ice cold cell suspension  (50’000 cells) in EDM10 (2.5 parts) with Matrigel (1 
part), plating in 3 cm culture dishes which were subsequently incubated for 6 days at 37°C.  
Images were obtained using a 5X objective in phase contrast.   
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4.5 SDS-PAGE and immunoblot analysis 
 
Electrophoretic separation of proteins was performed by discontinuous Laemmli SDS-PAGE 
using the Mini-PROTEAN
®
 II electrophoresis cell (Bio-Rad) with an electrophoretic 
separation length of 7 cm. For immunoblot analysis 10% polyacrylamide gels were poured 
using research-grade 29:1-Acrylamide/ Bisacrylamide (Serva, Heidelberg, Germany). To 
ensure that equal amounts of protein were loaded, protein concentration was determined in 
advance by using a Bradford-based assay (Bio-Rad Protein Assay, Bio-Rad Laboratories 
GmbH, Munich, Germany) and/or estimated by Coomassie staining of gels run in parallel and 
confirmed in some cases by Ponceau S staining of Western blot membranes. 
For Western Blot analysis, proteins were separated by SDS-PAGE as described above 
and transferred onto nitrocellulose membranes (Schleicher & Schuell Inc., Dassel, Germany) 
using a semidry electroblotter (Bio-Rad). After transfer, the membranes were incubated for 1h 
in blocking solution (20 mM Tris pH 7.6, 140 mM NaCl, 0.05% Tween-20, 5% w/v non-fat 
dry milk) and then washed twice for 5 min with TBS-T (20 mM Tris pH 7.6, 140 mM NaCl, 
0.05% Tween-20). Primary antibodies were diluted with TBS-T containing 2% w/v BSA and 
the membranes were incubated overnight at 4°C with gentle agitation. After three 5 min-
washes with TBS-T, the membranes were incubated for 1h at room temperature with the 
secondary antibody diluted 1:20’000 in TBS-T containing 2% w/v BSA. After further 
washing the membranes three times for 5 min with TBS-T, the immunoreactive bands were 
visualized by chemiluminescence (using SuperSignal
®
 West Pico Chemiluminescent 
Substrate, Pierce, Rockford, IL, USA). A CCD camera system (Lumi-Imager™, Boehringer 
Mannheim, Germany) was used to detect the signal. 
In the case of reprobing membranes for a protein of different size from the protein 
detected first line, membranes were washed twice for 10 min with TBS-T and incubated again 
for 1h in blocking solution, then proceeded with the next primary antibody as described 
above. Alternatively, stripping was accomplished by incubation for 30 min at 50°C with 
gentle agitation in stripping buffer (62.5 mM Tris-HCl pH 6.7, 100 mM 2-mercaptoethanol, 
2% SDS), washing twice for 10 min with TBS-T followed by incubation for 1h in blocking 
solution prior to reprobing for a different protein. 
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4.6 Isolation of RNA and Northern blotting 
 
Total RNA was prepared from tissue samples and cells using the guanidinium-thiocynate 
extraction method described by Chomczynski and Sacchi [89]. In total, 5 µg of total RNA 
was denatured with glyoxal, electrophoresed on a 1% agarose gel and blotted to 
nitrocellulose. Equal loading was controlled by examination of ribosomal RNA bands 
following staining with acridine orange as previously described [90]. Probes for hybridization 
were prepared using the Random Primed Labeling Kit (Roche Diagnostics, Rotkreuz, 
Switzerland) including 
32
P-dCTP (800 Ci/mM; Amersham International, Little Chalfont, 
England) in the reaction and hybridization was carried out as previously described [90]. 
 
4.7 Antibodies 
 
A specific antibody against mouse β-casein was generously provided by Dr. Ernst Reichmann 
(Pediatric Surgery Research, University Hospital, Zurich, Switzerland). Affinity-purified 
antibodies specific for c-erbB2 (mouse, human and rat specific; Cat. No. 06-562), phospho 
Tyr-1248 HER2 (only human-specific), Akt/PKB (Cat. No. 07-416), phospho Ser-473 
Akt/PKBα (Cat. No. 05-736 ), phosphorylated ERK 1/2 (Cat. No. 05-481), and phospho Ser-
657 PKCα (Cat. No. 06-822) were obtained from Upstate (Lake Placid, NY, USA). Horse 
radish peroxidase-conjugated secondary antibodies against rabbit IgG (Cat. No. 12-348) and 
mouse IgG (Cat. No. 12-349) were obtained from Upstate.  
 
4.8 Immunohistochemistry 
 
Animals were sacrificed and the spleen, gastrocnemius muscle or primary tumor removed and 
fixed in 4% formaldehyde overnight. The next day the tissues were dehydrated through 
graded ethanols and toluene and embedded in paraffin for sectioning. From every block of 
tissue, fixed in formalin and embedded in paraffin, serial sections of 4 µm were cut. Serial 
sections were dewaxed in xylene and rehydrated through graded ethanols. Sections were 
heated in 10 mM citrate buffer pH 6.0 in a microwave oven for 10 min at defrost power (till 
the temperature reached 90 – 95°C) followed by 2 min at low power (to maintain temperature 
at 90 – 95°C), to allow the antigens to be unmasked. For quenching endogenous peroxidase 
the sections were then incubated in 3% hydrogen peroxide diluted in 50% methanol for 10 
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min at room temperature. Incubation for 1 hour with 6% horse serum in a humidified chamber 
was then performed to block non-specific binding.  
Sections were stained with anti-ErbB2 antibody (1:1000, Upstate, Lake Placid, NY, 
USA) overnight at 4°C. Negative controls were performed with 6 % horse serum (blocking 
solution) as primary antibody. Incubation with the secondary antibody, biotinylated 
polyclonal goat-anti-rabbit-immunoglobulin (DAKO A/S, Denmark) in a dilution of 1:300, 
was done for 45min. This was then followed by a conventional Avidin-Biotin-horseradish 
peroxidase complex staining procedure, finally detecting with diaminobenzidine as substrate. 
Slides were counterstained in haematoxylin. The sections were evaluated under a light 
microscope (Leitz DMRD) and pictures taken with a Leica DMRB/DC200 (CCD camera) and 
imported in Adobe Photoshop 7.0. 
 
4.9 The Constructs 
 
4.9.1 The rat NeuT plasmid 
 
The rat NeuT in pBabe
puro
 vector we received as a kind gift from Prof. Nancy Hynes 
(Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland). The accession 
number for rat NeuT sequence at the National Center for Biotechnology Information (NCBI) 
was NM_017003.1. 
 
4.9.2 The mouse c-erbB2 RIKEN plasmid 
 
We obtained the mouse c-erbB2 gene in a pFLCI vector in a collaboration with the Genome 
Exploration Research Group RIKEN, Japan. The NCBI database Accession Number for 
mouse c-erbB2 at that time was BC046811. 
By comparing to the human and rat homologs, we found it to contain a substitution 
(addition of 81 bp) causing a frameshift and a non-functional product. That this error was in 
fact present in the RIKEN clone could only be confirmed by comparison with a later 
submitted mouse c-erbB2 sequence that was entered into the NCBI as this project was 
midway along. With time, growing knowledge about the sequence of mouse c-erbB2 revealed 
a more and more realistic picture of the true sequence found in nature. Ultimately, the NCBI 
predicted a virtual sequence combining the various versions submitted so far. The alignment 
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of the initial mouse version (accession number BC046811) against this predicted version of 
mouse c-erbB2 (acc. no NM_001003817) (Fig. 10) as well as against human HER2 (acc no 
NM_004448.2) (Fig. 11) finally revealed a cloning artefact in the mouse sequence. The insert 
is not a repeated sequence of mouse c-erbB2, but is spurious. 
With Western blot using a commercially available anti-ErbB2 antibody (Upstate) it 
was impossible for us to detect the RIKEN construct when it was cloned in an expression 
vector: Although this antibody was prepared with a peptide from a region (amino acid 1243-
1255) that comes after the frameshift (which is at approximately AA 734), and therefore no 
signal would be expected, it does detect a weak band, which can also be detected in normal 
Line 31E mouse epithelial cells. 
 
Mouse c-erbB2 (old) = BC046811 containing the addition 
Mouse c-erbB2 (new) = NM_001003817 
 
 
c-erbB2(old)    2192 CCTAATCAAACGAAGGCGACAGAAGATCCGGAAGTATACCATGCGTAGGC   2241 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
c-erbB2(new)    2201 CCTAATCAAACGAAGGCGACAGAAGATCCGGAAGTATACCATGCGTAGGC   2250 
 
c-erbB2(old)    2242 TGCTGCAGGAGACCGAGGTGAGGCGTGCCGAGGGCCTCCTAGCACCCCCT   2291 
                     |||||||||||||||___________________________________ 
c-erbB2(new)    2251 TGCTGCAGGAGACCG-----------------------------------   2265 
 
c-erbB2(old)    2292 TGGCTTTGCAGCTAGCTGGGCATTCACCCTACCACCCTCTCGCTCCAGCT   2341 
                     _________________________________           __|||| 
c-erbB2(new)    2266 ----------------------------------------------AGCT   2269 
 
c-erbB2(old)    2342 GGTGGAGCCGCTGACGCCCAGTGGAGCTGTGCCCAACCAGGCTCAGATGC   2391 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
c-erbB2(new)    2270 GGTGGAGCCGCTGACGCCCAGTGGAGCTGTGCCCAACCAGGCTCAGATGC   2319 
 
 
Fig. 10. Nucleotide sequence alignment of initial versus predicted mouse c-erbB2. 
 
Mouse c-erbB2 (old) = BC046811 containing the addition 
Human HER2          = NM_004448.2 
 
mousec-erbB2    2176 TGGTGGTCATTGGAATCCTAATCAAACGAAGGCGACAGAAGATCCGGAAG   2225 
                     .|||||||.||||.|||||.|||||.|||.|||..||||||||||||||| 
humanHER-2      2241 GGGTGGTCTTTGGGATCCTCATCAAGCGACGGCAGCAGAAGATCCGGAAG   2290 
 
mousec-erbB2    2226 TATACCATGCGTAGGCTGCTGCAGGAGACCGAGGTGAGGCGTGCCGAGGG   2275 
                     ||.||.|||||.||.|||||||||||.||.|………………………………………………… 
humanHER-2      2291 TACACGATGCGGAGACTGCTGCAGGAAACGG-------------------   2321 
 
mousec-erbB2    2276 CCTCCTAGCACCCCCTTGGCTTTGCAGCTAGCTGGGCATTCACCCTACCA   2325 
                     …………………………………………………………………………………………………………………………………… 
humanHER-2      2322 --------------------------------------------------   2321 
 
mousec-erbB2    2326 CCCTCTCGCTCCAGCTGGTGGAGCCGCTGACGCCCAGTGGAGCTGTGCCC   2375 
                     ………………     …|||||||||||||||||||.||.||.|||||..||||| 
humanHER-2      2322 ------------AGCTGGTGGAGCCGCTGACACCTAGCGGAGCGATGCCC   2359 
 
mousec-erbB2    2376 AACCAGGCTCAGATGCGGATCCTAAAGGAGACAGAGCTAAGGAAGCTGAA   2425 
                     ||||||||.||||||||||||||.||.|||||.|||||.||||||.|||| 
humanHER-2      2360 AACCAGGCGCAGATGCGGATCCTGAAAGAGACGGAGCTGAGGAAGGTGAA   2409 
 
 
Fig. 11. Nucleotide sequence alignment of initial mouse c-erbB2 versus HER2. 
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Since the RIKEN clone is the only isolate available of the 
full length mouse c-erbB2 (4.7 kb), and our own initial 
efforts to clone the full-length mouse c-erbB2 were 
unsuccessful, we decided to correct the cloning error by 
doing a site-directed replacement of missing sequences. C-
erbB2 in the pcDNA vector was subcloned into 
pBluescript SK(±) (Stratagene, La Jolla, CA, USA). A 
pBluescript subclone was restricted with Bst1107I (which 
cuts c-erbB2 at position 2105) and BsiWI (cuts at position 
2444) to remove a fragment of 339 bp spanning the 
erroneous 81 bp addition region.  RNA isolated from a 
pool of 15 day mouse embryo liver, lung, intestine, kidney 
and heart was employed to prepare cDNA with Transcriptor Reverse Transcriptase (Roche, 
Cat. No. 03 531 317 001) using the primer sequence AGGCAGCCATAGGGCATAAG to 
obtain a fragment extending beyond the entire excised 339 bp sequence. A PCR reaction 
(Expand High Fidelity Plus PCR System; Roche, Cat. No. 3 300 242) was then performed 
with the cDNA using primers designed to contain restriction sites for Bst1107I (sense) and 
BsiWI (antisense). Finally, the PCR fragment obtained was restricted with Bst1107I and 
BsiWI (Fig. 12), purified and ligated into the previously restricted pBluescript c-erbB2. The 
resulting full-length “corrected” c-erbB2 was sequenced and the alignment to HER2 showed 
that the 81 bp addition had been removed successfully (Fig. 13). Finally we subcloned the 
corrected mouse c-erbB2 into the pBabe
puro
 retroviral vector. Biological activity was observed 
in cell culture indicating a functional protein and a protein of the correct size could be 
detected with a Western blot using commercially available anti-ErbB2 antibody (Upstate). 
 
 
c-erbB2seq  = from sequenced full-length corrected mouse c-erbB2 
Human HER-2 = NM_004448.2 
 
c-erbB2seq      2006 TGGTGGTCATTGGAATCCTAATCAAACGAAGGCGACAGAAGATCCGGAAG   2055 
                     .|||||||.||||.|||||.|||||.|||.|||..||||||||||||||| 
humanHER-2      2241 GGGTGGTCTTTGGGATCCTCATCAAGCGACGGCAGCAGAAGATCCGGAAG   2290 
 
c-erbB2seq      2056 TATACCATGCGTAGGCTGCTGCAGGAGACCGAGCTGGTGGAGCCGCTGAC   2105 
                     ||.||.|||||.||.|||||||||||.||.|||||||||||||||||||| 
humanHER-2      2291 TACACGATGCGGAGACTGCTGCAGGAAACGGAGCTGGTGGAGCCGCTGAC   2340 
 
c-erbB2seq      2106 GCCCAGTGGAGCTGTGCCCAACCAGGCTCAGATGCGGATCCTAAAGGAGA   2155 
                     .||.||.|||||..|||||||||||||.||||||||||||||.||.|||| 
humanHER-2      2341 ACCTAGCGGAGCGATGCCCAACCAGGCGCAGATGCGGATCCTGAAAGAGA   2390 
 
 
Fig. 13. Nucleotide sequence alignment of sequenced corrected mouse c-erbB2 versus HER2. 
Fig. 12. Bst1107I and BsiWI
restricted PCR fragment ~339 bp.
2322
2027
564
bp
λHindIII PCR
fragment
~ 340
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4.9.3 The pGEX2 construct 
 
In an attempt to obtain an antibody with a higher specificity against mouse c-erbB2 than the 
commercial antibody from Upstate, we decided to engineer a GEX construct containing a 
highly antigenic sequence of mouse c-erbB2 RIKEN. In order to determine roughly the best 
antigenic region in HER2/c-erbB2 protein [91], which is expected to be the extracellular 
domain, we examined the hydropathy plot of this protein (Fig. 14) [91]. The representation of 
hydrophobic and hydrophilic tendencies within the protein depicts the extracellular domain to 
be approximately from amino acid 1 to 600.  
 
 
Fig. 14. Kyte-Doolittle hydropathy plots of HER2 and c-erbB2. 
 
 
We then designed two primers spanning 380bp within this extracellularly exposed region. 
With a sense primer containing a BamHI restriction site and an antisense primer containing an 
EcoRI restriction site a fragment of 380bp was obtained through PCR (RIKENPCRsmall). 
This fragment was then ligated into the BamHI/ EcoRI cut polylinker of the pGEX2 vector 
and sequenced. The sequenced 380bp insert was compared to the published database version 
of mouse c-erbB2 and showed an identity of a 100% (mouse sequence nucleotides 1107-
1486). In addition RIKENPCRsmall has of course the usual degree of identity towards 
human, i.e. 86%, see Fig. 15. 
 
human HER-2 mouse c-erbB2 
transmembrane region 
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DNA 
 
human: 1150 ttctacggacgtgggatcctgcaccctcgtctgccccctgcacaaccaagaggtgacagc 1209 
             || ||||| |||||||||||||| || ||||| |||| | ||||||||||||| ||||| 
mouse: 1094 ctccacggaagtgggatcctgcactctggtctgtcccccgaacaaccaagaggtcacagc 1153 
 
                                                                         
human: 1210 agaggatggaacacagcggtgtgagaagtgcagcaagccctgtgcccgagtgtgctatgg 1269 
             ||||| |||||||||||||||||||| |||||||||||||||||  |||| |||||||| 
mouse: 1154 tgaggacggaacacagcggtgtgagaaatgcagcaagccctgtgctggagtatgctatgg 1213 
  
                                                                         
human: 1270 tctgggcatggagcacttgcgagaggtgagggcagttaccagtgccaatatccaggagtt 1329 
            |||||||||||||||| | |||| || ||||||  | ||||||| ||||||||||||||| 
mouse: 1214 tctgggcatggagcacctccgaggggcgagggccatcaccagtgacaatatccaggagtt 1273 
 
                                                                         
human: 1330 tgctggctgcaagaagatctttgggagcctggcatttctgccggagagctttgatgggga 1389 
            ||||||||||||||||||||||||||||||||||||| |||||||||||||||||||| | 
mouse: 1274 tgctggctgcaagaagatctttgggagcctggcatttttgccggagagctttgatgggaa 1333 
  
                                                                         
human: 1390 cccagcctccaacactgccccgctccagccagagcagctccaagtgtttgagactctgga 1449 
            |||  |||||  |  |||||| ||  |||||||||| ||||||||||| || || ||||| 
mouse: 1334 cccctcctccggcgttgccccactgaagccagagcatctccaagtgttcgaaaccctgga 1393 
 
                                                                         
human: 1450 agagatcacaggttacctatacatctcagcatggccggacagcctgcctgacctcagcgt 1509 
             ||||||||||||||||||||||| ||||||||||| || ||| | |  |||||||| || 
mouse: 1394 ggagatcacaggttacctatacatttcagcatggccagagagcttccaagacctcagtgt 1453 
 
                                                                         
human: 1510 cttccagaacctgcaagtaatccggggacgaattctgcacaatggcgcctactcgctgac 1569 
            |||||||||||| |  || || |||||||| ||||| ||  |||| || |||||  |||| 
mouse: 1454 cttccagaaccttcgggtcattcggggacggattctccatgatggtgcttactcattgac 1513 
 
 
identities in DNA fragment seq: 84.7% 
overall identity in full-length seq: 85% 
 
 
Protein 
 
humanHER-2       300 PYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEH    349 
                     |||||||:|||||||||.:|||||||||||||||||||||.||||||||| 
mousec-erbB2     301 PYNYLSTEVGSCTLVCPPNNQEVTAEDGTQRCEKCSKPCAGVCYGLGMEH    350 
 
humanHER-2       350 LREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQV    399 
                     ||..||:||.||||||||||||||||||||||||:|:|..|||:||.||| 
mousec-erbB2     351 LRGARAITSDNIQEFAGCKKIFGSLAFLPESFDGNPSSGVAPLKPEHLQV    400 
 
humanHER-2       400 FETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLG    449 
                     |||||||||||||||||:|..||||||||:||||||||:||||||||||| 
mousec-erbB2     401 FETLEEITGYLYISAWPESFQDLSVFQNLRVIRGRILHDGAYSLTLQGLG    450 
 
humanHER-2       450 ISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANR    499 
                     |..|||||||||||||||||.|||||||:|||||||||||||||||:.|| 
mousec-erbB2     451 IHSLGLRSLRELGSGLALIHRNTHLCFVNTVPWDQLFRNPHQALLHSGNR    500 
 
identities in protein fragment seq: 123/143 = 86% 
overall identity in full-length seq: 87.7% 
 
 
Fig. 15. pGEX2-construct of RIKEN PCR small – comparison to human. The highlighted part in yellow 
represents the 380 bp insert. 
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Furthermore, the new bacterial pGEX2 construct has been checked for translation into protein 
and concentration by induction with IPTG in E. coli DH5alpha bacteria and finally via 
Western blot. The insert 400bp ~ 14kDa protein sequences fused to the glycogene-S-
transferase gene 710bp ~ 26kDa is detectable as an approximately 40kDa protein, see Fig. 16. 
 
 
Fig. 16. IPTG induced and purified         Fig. 17. Lysates all Met-1 cells; mouse #50 
RIKENPCRsmallpGEX2cl12. Lane M = molecular size                 antiserum diluted 1:500; c-erb = mouse c- 
standard.             erbB2.         
  
The new RIKENPCRsmallpGex2 clone 12 construct was used to immunize two male FVB 
mice (#50 + #51) by injecting the purified antigen in an oil emulsion intradermally in aliquots 
at various injection sites scattered over the back of the animals. A booster dose has been given 
in week 3 performing the same procedure as described. Blood was collected from these mice 
in week 6 and the serum was analyzed for specific antibodies via Western Blot (Fig. 17). 
In order to gain larger amounts of antibody, we immunized two rabbits with a dose of 
100ug purified antigen followed by 5 repetitive boosters according to the procedure described 
above. Antibody from rabbit serum was affinity purified on small columns of Affigel 10 
which had been covalently coupled with PAGE-purified antigen. Antibody elution was with 
glycine buffer, pH 2.5, rapidly neutralized to pH 7 after collection of fractions. Antibody was 
checked via Western blot see Fig. 18A. 
 
 
 
#50 Upstate 
   ∅     c-erb HER2   ∅    HER2 
185 kDa 
M     purified   -             + 
        antigen 
RIKENPCRsmallpGEX2cl1
2 
~ 40 kDa 
IPTG induction 
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4.9.4 The human HER2 plasmid 
 
The human HER2 plasmid pcDNA3 we received as a kind gift of Dr. Ming-Fong Lin, 
University of Nebraska Medical Center, Omaha, NE, USA [92]. The sequence of the HER2 
gene is published and filed in the NCBI database currently under the accession number 
NM_004448.2 (total length 4624 bp CDS 239-4006). This version was originally submitted 
by Yamamoto et al. [93] in 1986, and derived from tumor. Interestingly, when compared to 
the sequence of the physiological human ErbB2 gene (acc. no DQ047380) the Yamamoto 
sequence does not show any mutations, supporting the presumption that the oncogenicity of 
HER2 from this human tumor sample did not rely on a mutation in the gene. We then 
subcloned HER2 into the retrovirally promoted pBabe
puro
 vector. 
 
4.9.5 Expression of c-erbB2 and HER2 in cultured cells 
 
We initially used the c-erbB2 and HER2 constructs in the pcDNA3 vector (Invitrogen, 
Carlsbad, CA, USA) under the regulation of a CMV promoter. Since after transfection, both 
genes were gradually lost upon prolonged culture or in vivo passage and since the efficiency 
of gene transfer was rather low, we changed the vector system to the retrovirally promoted 
pBabe
puro
 vector. Together with the rat NeuT plasmid we now dispose of a comparable set of 
Fig. 18. Expression of HER2 wt and c-erbB2 in Met-1/ 31E cells. A
detected with rabbit antisera RIKENPCRsmallpGEX2 1:1000. B detected 
with commercial a-ErbB2/HER2 rabbit polyclonal antibody, Upstate, 
cat.no 06-562. Concentrations of lysates were measured photometrically. 
c-erb = infected with mouse c-erbB2; V = pBabepuro vector.
Rabbit #1
Met-1 31E
Rabbit #2
185 kDa
185 kDa
HER2  c-erb V    HER2  c-erb
A
B 185 kDaUpstate
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plasmids which carry the homologs of ErbB2 as inserts. Expression of pBabe
puro
 constructs of 
c-erbB2 and HER2 in the cell lines Met-1 and Line 31E is stable as verified in Western blot 
analysis of cell lysates (Fig. 18B). The weak detection of the mouse c-erbB2 probably reflects 
a lower degree of sensitivity by the Upstate antibody, though the mouse construct was 
consistently less strongly expressed. Transcription of ErbB2 has been detected by Northern 
blot analysis (Fig. 19). The labelled probe for Fig. 19 was prepared from HER2 template. 
 
 
                                    
Fig. 19. RNA of HER/ErbB2 by Northern blot analysis. Ø = 
non-infected; V = infected with pBabepuro vector; c-erb = 
infected with mouse c-erbB2.
V HER2      c-erb Ø V       c-erb
31E Met1
 
 
4.9.6 Cloning a dominant-negative mutated human HER2 
 
According to the literature, HER2 expression can downregulate components of the MHC 
class I antigen-processing machinery [39,40], resulting in an immune escape phenotype of 
oncogene-transformed cells. This effect presumably occurs due to signaling of the HER2 
receptor. The downregulation of MHC class I products becomes manifest after times as short 
as 24 hrs, making this effect a possible hindrance for HER2 DNA vaccination strategies. 
Therefore, we decided to construct for use as antigen, and also as a negative control for the 
transformation phenotype of HER2, a mutant HER2 gene, lacking the sequence coding for the 
ATP-binding site of this tyrosine kinase receptor protein. This mutation results in an 
inactivation of the tyrosine kinase activity and consequently blocks the transforming activity 
otherwise inherent in the immunization. 
With four specially designed primers we used PCR to produce two fragments, i.e. the 
coding regions on either side of the ATP-phosphate binding loop GSGAFG, at amino acid 
positions 727-732 (nucleotides 2181-2196) [41]. The primers were designed to contain either 
a restriction site for SalI or HindIII, see Fig. 20, and produced fragments of 2.3kb or 1.9kb 
respectively (Fig. 21).  
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Upon ligation of the two SalI and HindIII restricted fragments, the mutant HER2 gene 
(mutHER2) was then subcloned into the retrovirally promoted pBabe
puro
 vector, restricted 
with SalI. The sequence lacked the amino acids 725-733 and had AA 734 converted from 
Valine to Leucine (Fig. 22), adding to our antigen one more possible foreign determinant in 
the context of the mouse immune system.  
 
 
  mutHER-2           6 TPSGAMPNQAQMRILKETELRKVK---------LYKGIWIPDGENVKIPV     46 
                       ||||||||||||||||||||||||         :|||||||||||||||| 
  HER-2 db         701 TPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPV    750 
 
 
Fig. 22. Protein alignment of mutHER2 (sequenced mutated HER2) and HER2 db (database version of HER2 acc 
no NM_004448.2) showing the deleted region and the non-matching Leucine. The ATP-phosphate binding loop is 
depicted in red letters. 
 
Virtual translation of the sequenced fragment into 
protein predicts a 1245 AA protein. The pBabe
puro
 
mutHER2 was used to infect cultured FVB 
fibroblasts and expression was checked via Western 
blot analysis (Fig. 23). The mutation does not 
interfere with recognition by the commercial 
antibody (Upstate) against c-erbB2 (prepared 
against peptides AA 1243-1255) and against 
phospho-ErbB2 (pTyr 1248). 
Fig. 21. PCR of human HER-2 
M marker λHindIII; 1 primer pair 
S1/AS1; 2 primer pair S2/AS2 #1 
fragment of ~2.3kb #2 fragment 
of ~1.9kb. 
2322 
2027 
564 
bp 
M       1       2 
#1 
#2 
Fig. 23. Expression of mutHER2 in early 
passage FVB fibroblasts. Detection with 
commercial anti-ErbB2/HER2 Ab 
(Upstate) 1:1000. 
FVB fibroblasts 
V    mutHER2 
185 kDa 
Fig. 20. Human HER-2 insert size approx. 4250 bp (full-length 1-4624). 
       Primer S1  Primer AS1  Primer S2               Primer AS2 
         SalI      HindIII         HindIII                      SalI 
region coding for ATP-binding site 
(2181-2196) 
Fragment #1 
2.3 kb 
Fragment #2 
1.9 kb 
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4.9.7 Retrovirus Constructs 
 
Retroviral constructs of HER2, dominant negative mutant HER2 and mouse c-erbB2 were all 
prepared in pBabe
puro
 [94]. For HER2, the insert was restricted with HindIII and blunted with 
Klenow enzyme.  For the mouse c-erbB2 RIKEN “corrected” clone, restriction was with SacI, 
followed by blunting with T4 polymerase, and isolation of the insert by a second restriction 
with EcoRV.  Finally, the blunted inserts were ligated into a blunted SnaBI pBabe
puro
 site. 
Helper-free infectious virus was produced using amphitrophic Phoenix packaging cells [95] 
kindly supplied by Dr. G. Nolan (Stanford University Medical Center, Stanford, CA). Line 
31E cells were infected with approximately 4*10
5
 infectious units on 2*10
6
 cells. For 
infection Polybrene was used at 8 ug/ml. Successfully infected cells were selected with 4 days 
treatment with puromycin (Sigma) at 2.5 ug/ml. Expression was tested with Northern and 
Western blots, and biological activity confirmed by cell biological assays.  
 
4.10    Immunological methods 
  
4.10.1 Vaccination protocols 
 
Protocol A: DNA into muscle 
4 weekly injections have been performed of each 100ug naked DNA HER2 wt plasmid 
(pcDNA3 vector, in 50ul water) into the gastrocnemius muscle of mice. The injections have 
been done alternately in the muscle of the left and the right leg. The control animals have 
been injected with 100ug of the empty vector. The mice were challenged two weeks after the 
last vaccination by injecting Met-1 tumor cells transfected with mouse c-erbB2 (25’000 cells) 
in the right mammary gland. In a variant of this protocol, some of the mice have been boosted 
with 100ug naked DNA HER2 wt plasmid into the gastrocnemius muscle two weeks after the 
challenge. Tumor growth has been monitored by measurements during the following month 
(Appendix C, graph 1). 
The experiment has been repeated with 5 weekly injections but no challenge. Two 
weeks after the last vaccination dose two mice of each group were sacrificed and the spleen 
has been removed for isolating lymphocytes, analyzed in the following for the presence of 
specific cytotoxic T lymphocytes by intracellular INFy staining as well as in a Cr-Release 
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Assay. The positive control run together with the samples were lymphocytes from LCMV-
infected mice being used in another study, the generous gift of Prof. A. Ochsenbein and Dr. 
M. Matter (Department of Clinical Research, University of Berne, Switzerland). Blood was 
taken before the first vaccination and one week after the last injection and analyzed for 
specific antibodies against HER2.  
 
Protocol B1: fibroblasts into spleen (with fibroblast booster i.p. day 18) 
In this protocol FVB 3T3 fibroblasts infected with HER2 wt were injected directly into the 
spleen (1*10
6
 cells in 50ul) followed by a booster dose of the same cells i.p. on day 18 (3*10
6
 
cells). 4 weeks after the intrasplenic vaccination tumors became visible by eye in the region of 
the spleen. Histology of the primary tumor emerging from the spleen showed clearly sarcoma 
cells and indicated that the aetiology of the tumours was mouse c-erbB2 transformed 3T3 
fibroblasts. Long-term culture following transfection with an oncogene can favour cell 
transformation, so we vaccinated the next set with fibroblasts irradiated with 5000rad until 
growth arrest. Radiation time was titrated. Mice have been boostered i.p. with the same cells 
(2*10
6
) on day 10, but no challenge has been performed. Irradiated fibroblasts didn’t 
transform and the spleens could be used for analysis of activated and/or specific CTLs. 
Lymphocytes isolated from the spleen 21 days after i.s. vaccination were analyzed for CTL 
against HER2 wt by intracellular INFy staining and Cr-Release Assay. The positive control 
run together with the samples were lymphocytes from an LCMV-infected memory mouse as 
been used in another study. Tumor growth has not been determined in these groups. 
 
Protocol B2: low passage fibroblasts inf mutHER2 into spleen 
The achievement of a mutated HER2 together with FVB fibroblasts of an early passage made 
the irradiation of the vaccine unnecessary, it prevented transformation successfully. The first 
group of animals was challenged with endogenous mouse c-erbB2 (Appendix C, graph 2), and 
the second with xenogeneic HER2 wt (graph 3). Whole serum as well as 
immunoprecipitation-purified serum has been analyzed for specific antibodies by Western 
blot. 
The injections of FVB fibroblasts into the spleen were often followed by rapid death, 
in most cases instantly after injection of the cells and always accompanied by signs of 
respiratory stress. Intrasplenic injections of fibroblasts seemed to cause more frequent deaths 
than injections of naked DNA. These observations together led to the presumption of an 
embolus reaching the lungs. In an investigation of the abdomen of two mice a focal 
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hemorrhagic necrosis of the left liver lobe with signs of autolysis could be detected. This high 
death rate during surgery was the reason why we abandoned this protocol and concentrated on 
intrasplenic naked DNA injections. 
 
Protocol C1: DNA into spleen + electroporation 
Each animal received 80ug of naked mutHER2 DNA (30ul) into the spleen followed by 
electroporation of the injection site. There was no booster dose in this protocol. Mice were 
challenged in week 3 with either endogenous mouse c-erbB2 (Appendix C, graph 4) or 
xenogeneic HER2 wt (graph 5). Serum was analyzed by Western blot.  
 
Protocol C2: DNA into spleen with boost into muscle + electroporation 
The same protocol as C1 described above, except that mice were boostered in the 
gastrocnemius muscle with electroporation of the muscle and that all the animals have been 
challenged with HER2 wt. The schedule of first dose, booster and challenge was either week 
0 – 2 – 4 (Fig. 24) or 0 – 3 – 6 (Appendix C, graph 6). Serum was analyzed by Western blot.  
 
Fig. 24. Protocol C2: DNA into spleen with boost into muscle + electroporation. EP = electroporation; 
mgl = injected into the mammary gland. 
 
 
Protocol D: 31E cells into peritoneum with boost i.p. 
This last immunization attempt has been designed to represent just a proof of principle and 
does not claim to stand as a model for pre-clinical treatment in human. 4*10
6
 31E cells 
infected with either mutHER2 or pBabe
puro
 were injected into the peritoneal cavity. An 
identical dose has been injected as booster two weeks later. One group of animals was 
challenged with Met-1 tumor expressing c-erbB2, the other group with Met-1 expressing 
HER2 in week 5 (see chapter 5.1, Fig. 25). 

2 40
Challenge:
Met1 inf. HER-2wt
(10‘000 cells) mgl
observation for
tumor growthbleed and check for antibodies


8 weeks
Vaccination :
mutHER-2 DNA 
(80ug) i.s. + EP
Booster :
mutHER-2 DNA 
(80ug) i.m. + EP
 
6
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4.10.2 Isolation of lymphocytes 
 
Mice were sacrificed and a fold of skin was cut from its right side slightly towards the back. 
The spleen was carefully separated from the pancreas in order to prevent any enzymatic 
damage of spleen cells. The spleen was then removed and put in Eagle’s Dulbecco-Modified 
culture medium supplemented with 2% foetal calf serum (EDM2%) on ice. The spleen gets 
poured on top of a sterile wire grid placed in a Petri dish and smashed with the plunger of a 
sterile syringe until most of the tissue has passed through the grid. The cell suspension gets 
centrifuged in a quick spin of 500rpm at room temperature to remove the remaining tissue 
debris. The cell suspension is centrifuged with 1200rpm at 4°C for 5min and the pellet 
resuspended in Iscove’s Modified Dulbecco’s Medium supplemented with 10% foetal calf 
serum and 0.05mM β-mercaptoethanol (IMDM 10% βME). In the mean a number of 20*10
6
 
lymphocytes could have been isolated per spleen by this procedure. 
 
4.10.3 The Intracellular Interferon γ Staining 
 
In this protocol, lymphocytes are first activated in vitro, stained for the surface antigens CD8 
and CD4, then fixed with paraformaldehyde to stabilize the cell membrane and reversibly 
permeabilized with the detergent saponin to allow anti-interferon γ (INFγ) antibodies to stain 
intracellularly. The in vitro stimulation of the lymphocytes is required since cytokine levels 
are typically too low in resting cells. For detection of intracellular INFγ that has been 
produced in response to in vitro stimulation, it is necessary to block secretion of INFγ with 
protein transport inhibitors such as BrefeldinA, which keeps the INFγ inside the endoplasmic 
reticulum. INFγ, CD8 and CD4 are finally detected by flow cytometry. 
Briefly, 1*10
6
 lymphocytes isolated as described in 4.10.2, resuspended in IMDM 
10% βME and supplemented with 100 U/ml IL-2 (received as a gift from Prof. Ochsenbein, 
DKF Bern) and 20 ug/ml BrefeldinA (Sigma, Germany) were restimulated for 5 hours on 
adherent stimulator cells in a 48-well plate (1*10
5
 cells/ well). Two different stimulator cells 
were tested, FVB fibroblasts transfected with HER2 wt and Met-1 tumor cells transfected 
with mouse c-erbB2. A set of non-restimulated samples (on normal FVB fibroblasts) has been 
run in parallel in order to spot the effect of the specific stimulus. All samples have been run in 
duplicate.  
53 
Following restimulation and transfer to a round bottom 96-well plate, lymphocytes were 
stained with the antibodies CD8-PE and CD4-PE (eBioscience) diluted 1:600 in FACS buffer. 
Membranes and bound antibodies were fixed with 1% paraformaldehyde (Merck-Schuchardt, 
Munich, Germany) before permeabilizing the cells with 0.1% saponin (Sigma, Germany). 
Intracellular INFγ was stained with anti INFγ-FITC antibody diluted 1:300 (eBioscience). 
Detection was done by flow cytometry in 500 ul FACS Buffer in 5 ml Polystyrene Round-
Bottom Tubes (Falcon 35 2058, Becton Dickinson). 
As internal controls served unstained lymphocytes, each dye used for the FACS scan 
separate as well as FACS buffer only. The positive control consisted of splenocytes from an 
LCMV infected mouse as used in another study. Restimulation was done with peptide p33 
(main epitope of LCMV activating CD8) or p13 (activating CD4). 
 
4.10.4 The Chromium Release Assay 
 
Stimulator cells were FVB fibroblasts transfected with HER2 wt or untransfected as control. 
For better antigen presentation stimulator cells have been stopped in proliferation by 
irradiating with 5000 rad. Radiation time has been titrated. 0.5*10
6
 stimulator cells were 
cultured for 24 hours in 35mm mini culture dishes. Lymphocytes are prepared and 
resuspended to 2.5*10
6
 cells/ml in IMDM 10% βME (see 4.10.2) and supplemented with IL-2 
at 50 U/ml. Stimulator cell cultures were supplied with 2.5*10
6
 lymphocytes each and 
incubated at 37°C for five days. An IL-2 control (without stimulator cells) has been run in 
parallel in order to exclude unspecific lymphocyte stimulation through IL-2. Irradiated target 
cell suspensions, FVB fibroblasts transfected with HER2 wt or untransfected as control were 
plated out to 7000 cells per 96-well on day 4. On day 5 target cells were loaded with 
chromium-51 (Amersham Biosciences, Germany) approximately 12 uCi/ 2*10
5
 targets at 
37°C for 3h. The 5 days stimulated lymphocytes are given onto the target cells in a row of 
dilutions and were incubated at 37°C for 6 hours. Specific killing was observed in Kontrogel 
Scintillator Cocktail (Kontron Analytic, Zurich, Switzerland) using a liquid scintillation 
counter (Packard, Downers Grove, IL, USA). The positive control consisted of splenocytes 
from an LCMV infected mouse, see 4.10.3. Cell wall dissolving NP40 0.1% was used as 
maximum release control. Minimum release was assessed with samples containing no 
lymphocytes. A polystyrene control without cells was run in parallel. 
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4.10.5 Antibody detection 
 
Western Blots with 31E cells infected with wild-type HER2 or non-infected were probed with 
mouse sera in a dilution of 1:200. The positive control consisted of a strip with the same 
lysates probed with commercial anti-ErbB2 antibody (Upstate). 
 
 
5 Results and Discussion 
 
5.1 Part I – A xenogeneic HER2 DNA vaccination approach 
 
An overview of the tested immunization protocols is displayed in Table 2. The outcomes of 
these experiments will be very briefly summarized below. 
 Protocol A: No specific CD8(+) and CD4(+) T lymphocytes could be detected by 
intracellular INFy staining and no specific killing was observed in a Cr-Release Assay in 
vaccinated mice (data not shown). The analyzed sera didn’t show any specific antibodies 
against HER2. In order to enhance the immune stimulatory effect of the vaccine, we changed 
the application route to a direct presentation of the antigen to secondary lymphoid organs, 
such as the spleen or the mesenteric lymphnodes, as described in Protocols B1-D. 
Protocol B1: The FVB fibroblasts as vaccine carrier had to be irradiated prior to 
injection into the spleen in order to prevent formation of sarcoma tumors. Lymphocytes 
isolated from the spleen 21 days after i.s. vaccination and analyzed for CTL against HER2 wt 
did not show any significant difference between vaccinated and control group. Neither 
intracellular INFy staining nor Cr-Release Assay could detect specific T lymphocytes in 
vaccinated mice. Tumor growth has not been determined in these groups. 
Protocol B2: Since we employed the dominant negative mutated HER2 in FVB 
fibroblasts of an early passage, irradiation of the immunizing cells was unnecessary. In fact 
this modification of the procedure prevented the transformation of fibroblasts successfully. 
Control animals #26-32 displayed an interesting, significantly reduced tumor growth 
compared to the vaccinated group (animals #33-38), see Appendix C, graph 3. The probability 
for the null-hypothesis 20 days after the challenge is low (P = 0.0089), as calculated with the 
Mann-Whitney U-Test. This was our first observation suggesting the vaccination procedure 
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might in fact favor the growth of tumor. The high death rate during surgery was the reason 
why we abandoned this protocol and concentrated on intrasplenic naked DNA injections. 
 Protocols C1 and C2: Sera have been repeatedly analyzed for specific antibodies 
using Western blotting. Specific antibodies were detected in a small subset of the mice, but 
were neither statistically significant nor reproducible. Tumor growth was comparable between 
vaccinated and control groups (see Appendix C, graph 6). 
 Protocol D: In this vaccination attempt, designed as a proof of principle, we see more 
frequent tumor development in the vaccinated mice than in the control groups, see Figure 25. 
The calculated probability for the null-hypothesis is low, P = 0.0139 for the Met-1 c-erbB2 
challenged group and P = 0.119 for the Met-1 HER2 group (both at day 40 after challenge). 
We were unsuccessful in measuring specific antibodies in the serum. 
  
 
Fig. 25. Growth curves for protocol D: The tumor challenge in graph 7 is c-erbB2 infected Met-1 tumor, 
whereas in graph 8 Met-1 is infected with HER2 wt.   
 
The observation in Protocols B2 and D, where vaccinated mice developed tumors more 
rapidly than the control animals, is nonetheless interesting. The explanation may be due to a 
mechanism in priming specific T lymphocytes in the secondary lymphoid organ. In fact, such 
a phenomenon has been previously described by Ochsenbein [34]. The ability of CTLs to 
extend tolerance to the antigen, especially when the encounter between antigen and CTLs is 
persistently high was discussed [34]. In such a situation, T cells stimulated to maximal 
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proliferation can consequently undergo a contraction phase, resulting in the deletion of all T 
cells specific for that antigen [34] (discussed in more detail in chapter 3.2.3). It is theoretically 
possible that the fibroblasts in Protocol B2, probably due to their size, reside longer in a dense 
tissue such as the spleen whereas naked DNA, taken up by APCs is processed rapidly and 
persists for a shorter time in the organ, thus limiting the contact to T cells. This could explain 
also why no such phenomenon was observed with the protocols of naked DNA injection into 
the spleen (Protocols C1 and C2). In Protocol D, epithelial cells infected with human HER2 
were injected into the peritoneal cavity. The antigen, once cross-presented to APCs, is 
priming T cells in the various secondary lymphoid organs located in the gastrointestinal tract. 
The gut-associated lymphoid tissue or GALT is equipped with a roughly equivalent number 
of lymphocytes to those in the spleen. The ErbB2 peptides are predominantly presented in 
mesenteric lymph nodes and Peyer’s patches, lymphoid follicles located in the mucosa of the 
small intestine. Thus, induction of tolerance in protocol D might be due to the high dose of 
vaccine (twice 4*10
6
 cells) and the potent priming occurring in the GALT. Tumor cells 
escaping the immune system by either downregulation or loss of ErbB2 receptors are less 
likely to play a role in our system since expression of ErbB2 in Met-1 cells has been 
monitored in cultures over a long period and was found to be stable. 
While we have performed many experiments and have suffered many 
disappointments, the vaccination approach would probably justify much further work. One 
possible line of further investigation would be the injection of more than one foreign ErbB2 
homolog antigen. This possibility might generate a stronger immune response and could be 
seen as an improvement of our tested vaccination schedules. The idea would be to engineer 
the same kinase deficient mutant in rat NeuT. Mice would be vaccinated first with mutHER2, 
receive a first boost with mutated NeuT and a second boost with both mutated genes 
combined. 
Another possible improvement of the vaccine design would include the use of 
syngeneic dendritic cells (DCs) as hosts for the antigenic DNA. DCs are believed to be the 
most potent antigen processing cells [96,97] and numerous successful vaccination studies 
relied on this system [98,99]. A recent publication describes stronger immune responses to 
NeuT using adenovirus NeuT-transfected dendritic cells compared to plasmid DNA [100]. 
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5.2 Part II – The cell differentiation and pathway project 
 
The results obtained in this part are subject to a manuscript prepared for publication.  See 
below.
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Appendix A: Abbreviations 
 
Akt Protein kinase B (PKB), a serine/threonine kinase activated by PI3K 
 
APC 
 
Antigen-presenting cell 
ASK1 Apoptosis-signal-regulating kinase 1 
 
CTL 
 
Cytotoxic T lymphocyte 
DC 
 
Dendritic cell 
Erk Extracellular signal-regulated kinase, a MAP kinase 
 
GM-CSF 
 
Granulocyte-macrophage colony-stimulating factor 
Grb2 
 
Growth-factor-receptor-bound protein 2 
HC 
 
hydrocortisone 
IHC 
 
Immunohistochemistry 
IL-2 
 
Interleukin 2 
IP3 Inositol-1,4,5-triphosphate 
 
IPTG Isopropyl-β-D-thiogalactosid (substrate of β-galactosidase) 
 
mAb Monoclonal antibody 
 
MHC 
 
Major histocompatibility complex 
mTOR Mammalian target of rapamycin, a 289kDa serine/threonine kinase 
 
NSCLC 
 
Non-small-cell lung carcinoma 
p21
Cip1/WAF1
 A senescence-associated cyclin-dependent kinase inhibitor 
 
p38 High osmolarity glycerol response kinase (p38α, β, γ, δ), a MAP kinase as well as a 
stress-activated protein kinase (SAPK), responds to stress 
 
PRL 
 
prolactin 
RTK Receptor tyrosine kinase 
 
SH2 Family of intracellular proteins which have in common a sequence of about 100 aa, 
known as the SH2 domain, standing for src-homology 
(examples: Grb/ GAP/ PLCy/ PI3-Kinase/ Src…) 
 
SHC Src homology 2 domain containing transforming protein 
 
Src An intracellular tyrosine kinase, pp60
c-src
, human c-Src is a proto-oncogene 
 
STATs 
 
Signal transducer and activator of transcription proteins; signaling effectors often 
associated with EGFR activation 
WAP 
 
Whey acidic protein 
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Appendix B: Cell lysis buffer 
 
 
Modified Radioimmunoprecipitation (RIPA) buffer 
 
 
Base ingredients: 
• 1X modified PBS (see below) 
• 1% Triton X-100 
• 0.25% Na-deoxycholate 
 
 
Protease inhibitors: 
• 1 µg/ml leupeptin 
• 1 µg/ml aprotinin  
• 1 mM EDTA 
• 1 mM EGTA 
• 1 mM β-glycerophosphate 
• 1 mM 6-aminohexanoic acid 
• 1 mM PMSF (added just prior to use) 
 
 
Phosphatase inhibitors: 
• 1 mM activated Na-orthovanadate 
• 1 mM NaF 
 
 
 
PBS (10X): 0.1 M Na2HPO4, 17.6 mM KH2PO4, 1.37 M NaCl, 26.9 mM KCl 
(the pH was adjusted to 7.4 with HCl) 
62 
 
Appendix C: Tumor growth curves 
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Abstract 
ErbB2 is an orphan receptor tyrosine kinase which can dimerize with other ligand-
activated members of the EGF receptor family to signal in pathways inducing cell 
proliferation. Frequently overexpressed in breast cancer and other human cancers, 
homologs of ErbB2 are oncogenes in different animal species which have been 
studied for their contribution to the development of carcinomas. We have examined 
the phenotypes induced by several such ErbB2 homologs in the Line 31E mouse 
mammary epithelial cell model which is capable of differentiation in vitro in response 
to lactogenic hormones to undergo dome formation and to produce β-casein. 
Included in this comparative study are the functional proto-oncogene mouse c-erbB2, 
HER2, a human homolog overexpressed in breast cancer and the mutated rat 
homolog, NeuT, which is known to be oncogenic. 
Line 31 E mammary epithelial cells were infected with retroviral pBabepuro constructs 
of the different ErbB2 homologs. While the cells expressing the homologs remain 
responsive to EGF ligand in terms of Akt/PKB, ERK 1/2 and PKCα phosphorylation, a 
somewhat elevated basal phosphorylation level in the absence of ligand was 
apparent for Akt/PKB and ERK 1/2 with mouse c-erbB2-, HER2- and NeuT-infected 
cells, but not with the dominant negative mutant HER2. Typical features of epithelial 
intercellular organization, such as transmonolayer electrical resistance (TER, a 
measure of the density of tight junctions) and dome formation, were disturbed by 
ErbB2 expression. While the dominant negative mutant of HER2 had no phenotypic 
effect, both TER and dome formation were reduced to some degree by all three of 
the functional ErbB2 homologs, most dramatically by NeuT. While expression of both 
the mouse proto-oncogene c-erbB2 and HER2 resulted in significant inhibition of β-
casein mRNA and protein levels when the mouse mammary epithelial cells received 
lactogenic hormone stimulation, NeuT completely abrogated β-casein production and 
caused oncogenic transformation as evidenced by large colonies in soft agar and 
Matrigel suspension culture.  
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Introduction 
 
Several types of cancers overexpress ErbB2.1 For example, invasive ductal breast 
cancer shows gene amplification in approximately 30% of all cases2 while the 
comedo-type ductal carcinoma in situ, a non-invasive, premalignant mammary tumor, 
shows a much higher proportion (80–85%).3 In general one can say that 
overexpression correlates with tumour size, probability of spread of tumour to lymph 
nodes, higher tumor grade, higher percentage of S-phase cells, aneuploidy and loss 
of steroid hormone receptor expression. Together these characteristics imply that 
ErbB2 overexpression probably confers a strong proliferative advantage to tumor 
cells since the output of the ErbB signalling network impacts functions ranging from 
cell division and migration (both associated with tumorigenesis) to adhesion, 
differentiation and apoptosis.4  
Three sorts of ErbB2 gene isolates have been made over the years: Neu, a mutated 
form of the rat ErbB2 homolog was cloned from neuroblastomas,5 HER2, not 
mutated, but repeatedly isolated from breast cancer biopsies,6 and mouse c-erbB2, 
the normal mouse homolog.7 Two different unrelated mutations have been found in 
Neu, the rat ErbB2 homolog, each leading to the onset of transformation. Firstly, 
Bargmann et al.5 found a single point mutation in the transmembrane domain of Neu 
in chemically induced rat neuroectodermal tumors. Their findings demonstrated that 
alterations in the transmembrane segment of rat Neu can have profound effects on 
its biological activity and transforming ability. The single-point mutation (GTG to 
GAG) results in the valine to glutamic acid amino acid substitution at amino acid 664 
in the transmembrane domain of the receptor. This point mutation apparently mimics 
ligand induction of receptor activation and results in the activation of the receptor 
tyrosine kinase with constitutive receptor dimerization. This mutation was the only 
difference found between the oncogene Neu and the rat proto-oncogene. Later, 
however, in tumors from transgenic MMTV/Neu mice, a second mutation was 
discovered in the extracellular region of Neu, resulting in a constitutively-activated 
receptor capable of transforming Rat-1 fibroblasts.8  
In human cancers, activation of wild-type ErbB2 occurs through overexpression, 
generally due to genomic amplification of the ErbB2 proto-oncogene.2 Holbro and 
Hynes9 postulate that high levels of the wild-type receptor are responsible for the 
oncogenic phenotype by promoting spontaneous homodimerization and constitutive 
ErbB2 activation. Recently, somatic mutations in the kinase domain of human ErbB2 
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have, however, been identified in a small subset (approximately 5%) of primary lung 
tumors (NSCLCs).10  
Human mammary epithelial cells overexpressing HER2 have been shown to exhibit 
in vitro two major changes in cellular behaviour with high relevance to tumorigenesis; 
firstly, the epithelial-to-mesenchymal transition (EMT), and secondly, anchorage 
independent growth (AIG).11, 12 In EMT, the epithelial characteristics of the cells, such 
as cell polarity, the presence of adherens junctions, tight junctions and desmosomes, 
and expression of many epithelium-specific proteins, are lost and replaced with those 
of a more or less mesenchymal phenotype.11 An important characteristic of EMT is 
the down-regulation of E-cadherin expression. Furthermore, functional a disturbance 
in gap junctional communication between epithelial cells owing to phosphorylation 
and down-regulation of connexin 43 protein has been reported.13-15 AIG is usually 
detected by the classical parameter of growth capacity in soft agar. Jenndahl et al.12 
argue that EMT is a critical phenotypic change required for AIG to develop in the 
course of ErbB2 signalling. When HER2 is overexpressed in an infected human 
breast cancer cell line (MDA-MB-231), it appears to synergize with the TGFβ 
pathway to potentiate pro-invasion, angiogenesis, and EMT.16  
ErbB2-induced EMT has been shown to be mediated by and dependent on c-Src 
with normal epithelial kidney cells (MDCK).17 The oncogenic behaviour of ErbB2-
expressing mammary tumor cells seems to be a consequence of Src activation 
which, further down the pathway is also responsible for PKCα activation. Src and 
PKCα are present as a physical complex, and treatment with inhibitors of either Src 
or PKCα suppresses tumor cell invasion.18  
Mammary gland functional differentiation occurs with distinct morphological and 
molecular changes of the epithelial cells and allows for the production and secretion 
of milk. Thus, the secretory alveolar cells represent the final cellular state of the life-
spanning multistep differentiation process within the mammary gland. The 
differentiation steps taking place during pregnancy and lactation are characterized by 
the sequential activation of genes encoding the milk proteins such as β-casein, whey 
acidic protein (WAP) and α-lactalbumin. Mammary gland development in response to 
lactogenic hormones in vitro is known to be accompanied by distinct morphological 
changes in the monolayers forming structures called domes. Zucchi et al.19 have 
correlated the dome formation in vitro with differentiation processes occurring in the 
mammary gland during pregnancy. Dome formation was shown to be inducible by the 
Epithelial Cells Expressing ErbB2 Homologs 5
lactogenic hormones insulin, hydrocortisone and prolactin preceding expression of 
the milk protein β-casein, which is a specific marker of the initial stage of mammary 
gland functional differentiation.20 
In order to learn about the influence of ErbB2 on normal, polarized mammary 
epithelial cells in culture, we decided to study the differentiation in vitro of the Line 31 
mouse mammary epithelial cells,20, 21 using retroviral constructs of mouse c-erbB2, 
HER2 and NeuT in order to study the behavioural phenotype exerted by the different 
isolates. 
Epithelial Cells Expressing ErbB2 Homologs 6
Materials and Methods 
 
Cell Culture 
 
The mouse mammary epithelial (31E) and fibroblast-like mammary stem cell (30F) 
lines were established from BALB/c mice and characterized by Dr. Ernst Reichmann 
in our laboratory as described previously.20 Cells were cultured in Eagle’s Dulbecco-
Modified medium enriched by 10% foetal calf serum (EDM10) and supplemented with 
EGF (10 ng/ml). The cells used in the EGF-stimulation experiments had been 
deprived of EGF one week before and subjected to serum starvation (2% FKS) 20 - 
24 hrs prior to stimulation with EGF. Ligand stimulation was performed with 40 ng/ml 
EGF for 0, 2, 5, 15 and 30 min. 
For preparation of cell lysates, confluent cells from 5 cm plates were washed with 
phosphate buffered saline (PBS) and incubated at 4° C for 10 min in 1 ml of modified 
RIPA lysis buffer (PBS with 1% Triton X-100, 0.25% Na-deoxycholate, 1 ug/ml each 
leupeptin and aprotinin, 1 mM each EDTA, EGTA, β-glycerophosphate, 6-
aminohexanoic acid, NaF and sodium-orthovanadate). PMSF was added to 1 mM 
immediately before use. Following Dounce homogenisation, samples were 
centrifuged at 20’000 x g for 10 min and the supernatants collected. After 
determination of protein concentration using the Bradford-based Bio-Rad Protein 
Assay (Bio-Rad Laboratories GmbH, Munich, Germany), the lysates were diluted to 
1X SDS-PAGE sample buffer (80mM Tris pH 6.8, 2% SDS, 10% glycerol, 2% 2-
mercaptoethanol and 0.02% bromphenol blue) and boiled for 2 min before 
electrophoresis on 10% polyacrylamide gels.  
 
In Vitro Differentiation Assays, Soft agar and Matrigel growth assays 
 
In order to induce functional in vitro differentiation of Line 31E mouse mammary 
epithelial cells expressing the various ErbB2 constructs, co-cultures were prepared 
with Line 30F cells as described.20 The co-cultures were established with densities of 
Line 31E to Line 30F in the ratio of 4:1. After culture for 48 hrs initially in medium 
supplemented with EGF (10 ng/ml), cells were changed for 24 hrs to EDM with 3% 
foetal calf serum, 5 ug/ml insulin, 1 ug/ml hydrocortisone and 5 ug/ml ovine prolactin. 
Thereafter, supernatants were taken and cells were lysed using RIPA lysis buffer for 
determination of β-casein in Western blots.  
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For determination of the electrical resistance across the monolayers of pure cultures 
of Line 31E cells infected with the different ErbB2 constructs, cells were grown to 
confluence on cellulose nitrate filter inserts (diameter 2.2 cm) in 6-well plates as 
previously described.21 Resistance measurements were obtained with the Millipore 
(Bedford, MA., USA) Millicell-ERS instrument, essentially a milli-volt/ohmmeter that 
provides an alternating voltage source to minimize cell damage. 
Cell morphology of 31E cells on plastic substrate, expressing the different ErbB2 
homologs was recorded using a 20x objective in phase contrast after 3 days and 6 
days in culture with lactogenic hormones. Culture in soft agar was performed by 
mixing gently 50’000 cells in EDM10 at room temperature with EDM10/Noble agar at 
42° C to give a final concentration of 0.37% Noble agar. 3 cm culture dishes which 
had been covered with 0.8 ml EDM10 containing 1% Noble agar as a hard 
underlayer, were overlayed with 1.5 ml of the cell suspension. Incubation was for 6 
days at 37° C in a conventional CO2 incubator. Culture in Matrigel (growth factor 
depleted; BD Biosciences, Bedford, MA, USA) was also performed according to the 
manufacturer’s instructions by diluting an ice cold cell suspension (with 50’000 cells) 
in EDM10 (2.5 parts) with Matrigel (1 part), plating in 3 cm culture dishes which were 
subsequently incubated for 6 days at 37° C. Images of suspension culture colonies 
were obtained using a 5X objective in phase contrast.   
SDS-PAGE and Immunoblot Analysis 
 
Electrophoretic separation of proteins was performed by discontinuous Laemmli 
SDS-PAGE using the Mini-PROTEAN® II electrophoresis cell (Bio-Rad) with an 
electrophoretic separation length of 7 cm. For immunoblot analysis 10% 
polyacrylamide gels were poured using research-grade 29:1-Acrylamide/ 
Bisacrylamide (Serva, Heidelberg, Germany).  
For Western Blot analysis, proteins were separated by SDS-PAGE as described 
above and transferred onto nitrocellulose membranes (Schleicher & Schuell Inc., 
Dassel, Germany) using a semidry electroblotter (Bio-Rad). After transfer, to ensure 
that equal amounts of protein were loaded, protein concentration was confirmed by 
Ponceau S staining of Western blot membranes. The membranes were incubated for 
1h in blocking solution (20 mM Tris pH 7.6, 140 mM NaCl, 0.05% Tween-20, 5% w/v 
non-fat dry milk) and then washed twice for 5 min with TBS-T (20 mM Tris pH 7.6, 
140 mM NaCl, 0.05% Tween-20). Primary antibodies were diluted with TBS-T 
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containing 2% w/v bovine serum albumin (BSA) (Fraction V, Sigma) and the 
membranes were incubated overnight at 4°C with gentle agitation. After three 5 min-
washes with TBS-T, the membranes were incubated for 1h at room temperature with 
the secondary antibody, horse radish peroxidase-conjugated anti-mouse or anti-
rabbit antibody diluted 1:10’000 in TBS-T containing 2% w/v BSA. After further 
washing the membranes three times for 5 min with TBS-T, the immunoreactive bands 
were visualized by chemiluminescence using SuperSignal® West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL, USA). A CCD camera system 
(Lumi-Imager™, Roche Diagnostics, Rotkreuz, Switzerland) was used to detect the 
signal. 
For reprobing membranes for proteins of a different size, membranes were washed 
twice for 10 min with TBS-T and incubated again for 1h in blocking solution, before 
proceeding with the next primary antibody as described above. Alternatively, stripping 
was accomplished by incubation for 30 min at 50°C with gentle agitation in stripping 
buffer (62.5 mM Tris-HCl pH 6.7, 100 mM 2-mercaptoethanol, 2% SDS), washing 
twice for 10 min with TBS-T followed by incubation for 1h in blocking solution prior to 
reprobing for a different protein. 
 
Antibodies 
A polyclonal rabbit antibody against mouse β-casein was generously provided by Dr. 
Ernst Reichmann (Pediatric Surgery Research, University Hospital, Zurich, 
Switzerland). 
Affinity-purified antibodies specific for c-erbB2 (mouse, human and rat specific), 
Akt/PKB phospho-Ser-473 Akt/PKBα, MAP kinase phospho ERK 1/2 (monoclonal 
12D4), and PKCα phospho-Ser-657 were all obtained from Upstate (Chemikon, Lake 
Placid, NY). Horse radish peroxidase-conjugated secondary antibodies against rabbit 
IgG or mouse IgG were also obtained from Upstate.  
Isolation of RNA and Northern blotting 
Total RNA was prepared from tissue samples and cells using the guanidinium-
thiocyanate extraction method described by Chomczynski and Sacchi.22 5 µg of total 
RNA was denatured with glyoxal, electrophoresed on a 1% agarose gel and blotted 
to nitrocellulose. Equal loading was controlled by examination of ribosomal RNA 
bands following staining with acridine orange, but immediately prior to blotting as 
previously described.23 Probes for hybridization were prepared using the Random 
Epithelial Cells Expressing ErbB2 Homologs 9
Primed Labelling Kit (Roche) including 32P-dCTP (800 Ci/mM; Amersham 
International, Little Chalfont, England) in the reaction and hybridization was carried 
out as previously described. 
 
Constructs 
The mouse c-erbB2 RIKEN plasmid 
 
We obtained the mouse c-erbB2 gene in the pFLCI vector in a collaboration with Dr 
Yoshihide Hayashizaki, Genome Exploration Research Group, RIKEN, Japan (Clone 
ID D030063B12).7 The NCBI database Accession Number for mouse c-erbB2 at that 
time was BC046811. 
By comparing to the human and rat homologs, we found Clone D030063B12 to 
contain a substitution (addition of 81 bp) causing a frameshift and a non-functional 
product. This error could be established by comparison with an NCBI-predicted 
virtual sequence for mouse c-erbB2 (Accession No. NM_001003817) that was 
entered into the NCBI database after this project had begun. See Table 1 for the 
alignment. The 81 bp insert is not a repeated sequence of mouse c-erbB2, but is 
spurious. 
Since the RIKEN clone was the only isolate available of the full length mouse c-erbB2 
(4.7 kb), we decided to correct the cloning error by site-directed mutagenesis of the 
clone D030063B12. The RIKEN clone was first subcloned into pBluescript SK(±) 
(Stratagene, La Jolla, CA, USA). A pBluescript subclone was restricted with Bst1107I 
(restricts c-erbB2 at position 2105) and BsiWI (cuts at position 2444) to remove a 
fragment of 339 bp spanning the erroneous 81 bp addition region. RNA isolated from 
a pool of 15 day mouse embryo liver, lung, intestine, kidney and heart was employed 
to prepare cDNA with Transcriptor Reverse Transcriptase (Roche) using the primer 
sequence AGGCAGCCATAGGGCATAAG to obtain a fragment which extended 
beyond the entire excised 339 bp sequence. A PCR reaction (Expand High Fidelity 
Plus PCR System; Roche) was then performed with the cDNA using primers 
designed to contain restriction sites for Bst1107I (sense) and BsiWI (antisense). 
Finally, the PCR fragment obtained was restricted with Bst1107I and BsiWI, purified 
and ligated into the previously restricted pBluescript c-erbB2. The resulting full-length 
“corrected” c-erbB2 was sequenced and the alignment to human HER2 showed that 
the 81 bp addition had been removed successfully. Finally, we subcloned the 
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corrected mouse c-erbB2 into the pBabepuro retroviral vector.24 Biological activity was 
observed in cell culture indicating a functional protein and a protein of 185 kD could 
be detected with a Western blot using commercially available (Upstate) anti-c-erbB2 
antibody. 
The human HER2 plasmid 
 
The human HER2 plasmid pcDNA3 we received as a kind gift of Dr. Ming-Fong Lin, 
University of Nebraska Medical Center, Omaha, NE, USA.25 The sequence of the 
human HER2 gene is published and filed in the NCBI database under the Accession 
Number NM_004448.2 (total length 4624 bp; CDS 239-4006). This version was 
originally submitted to the NCBI by Yamamoto et al.6 in 1986, and derived from a 
human mammary tumor. Interestingly, when compared to the sequence of the 
physiological human ErbB2 gene (Accession No. DQ047380), the Yamamoto 
sequence does not show any mutations, thus, supporting the presumption that the 
oncogenicity of HER2 in this human tumor sample did not rely on a mutation in the 
gene.   
Construction of a Dominant-negative mutated human HER2 
 
We decided to construct as a negative control for the transformation phenotype of 
HER2, a dominant negative mutant of the HER2 gene lacking the sequence coding 
for the ATP-binding site of this tyrosine kinase receptor protein. This mutation results 
in an inactivation of the tyrosine kinase activity and consequently blocks the 
transforming activity. With four specially designed primers we used high fidelity PCR 
to produce two fragments, i.e. the coding regions on either side of the ATP-
phosphate binding loop GSGAFG, at amino acid positions 727-732 (nucleotides 
2181-2196). The primers were designed to contain restriction sites for SalI and 
HindIII, respectively, and produced fragments of 2.3kb and 1.9kb, respectively, which 
when re-ligated restored a full-length HER2 construct, coding for a protein lacking 
only 6 amino acids, with a single mutation replacing the valine at position 733 with 
alanine.  
 
 
Epithelial Cells Expressing ErbB2 Homologs 11
The rat NeuT plasmid 
 
The rat NeuT in the pBabepuro vector was the generous gift of Prof. Nancy Hynes 
(Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland).  
 
Retrovirus Constructs 
 
Retroviral constructs of HER2, dominant negative mutant HER2 (designated MUT) 
and mouse c-erbB2 were all prepared in pBabepuro.24 For HER2, the insert was 
restricted with HindIII blunted with Klenow enzyme.  For the mouse c-erbB2 RIKEN 
“corrected” clone, restriction was with SacI, followed by blunting with T4 polymerase, 
and isolation of the insert by a second restriction with EcoRV. Finally, the blunted 
inserts were ligated into a blunted SnaBI pBabepuro site. Helper-free infectious virus 
was produced using amphitrophic Phoenix packaging cells26 kindly supplied by Dr. G. 
Nolan (Stanford University Medical Center, Stanford, CA). Line 31E cells were 
infected with approximately 4x105 infectious units on 2x106 cells. For infection 
Polybrene was used at 8 ug/ml. Successfully infected cells were selected with 4 days 
treatment with puromycin (Sigma) at 2.5 ug/ml. Expression was tested with Northern 
and Western blots, and biological activity confirmed by cell biological assays.  
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Results 
 
We first examined effects of expression of the ErbB2 homologs on several signalling 
pathways one could expect to be perturbed. In order to obtain a baseline, Line 31E 
cells infected with the different ErbB2 homologs were compared without EGF ligand 
stimulation in Western blots of parallel, identical PAGE runs. The Western blot in Fig. 
1 demonstrates that with an antibody cross-reactive with all ErbB2 homologs, each of 
the constructs was well expressed. That equal loading was attained is apparent from 
the detection with Akt-specific antibody, while the two lower gels demonstrate that 
basal phosphorylation levels for Akt in the PI3 kinase pathway and ERK 1/2 in the 
MAP kinase pathway are elevated in Line 31E cells expressing the different ErbB2 
homologs, most strikingly with NeuT infected cells. PKCα phosphorylation was not 
stimulated in the absence of EGF ligand stimulation (data not shown). 
Fig. 2 illustrates the phosphorylation/activation of Akt, Erk 1/2 and PKCα following 
EGF ligand treatment for different times. Total Akt is shown in the first panel as an 
equal-loading control. Akt levels do not vary after treatment with the ligand, whereas 
Akt phosphorylation shows an increase within 2 minutes. Not surprisingly, the 
dominant negative mutant HER2 shows responses to EGF similar to cells expressing 
functional ErbB2, reflecting the inevitable effect owing to the endogenous EGF 
receptor-family members in Line 31 cells. In these normal epithelial cells, expression 
of EGF Receptor 1 (EGFR1), which is essential for any response by ErbB2 
homologs, at the same time complicates the interpretation of the results observed in 
the signalling pathways. Phospho-ERK 1/2 shows a rapid response to EGF, while 
PKCα phosphorylation is slower, but more dramatic, extending beyond 30 minutes 
after stimulation (Fig. 2). The significance of the results shown in Fig. 2 is that while 
basal receptor signalling (Fig. 1) can be detected for all the ErbB2 homologs even 
without ligand added, stronger responses can be induced in the pathway following 
EGF stimulation. 
The modest effects elicited in the PI3 kinase and MAP kinase pathways by 
expression of ErbB2 homologs do, however, show major consequences in the cell 
biological phenotype. Co-cultures of Line 31E and Line 30F cells (in the proportions 
4:1) show characteristic in vitro differentiation behaviour in response to lactogenic 
hormones. Fig. 3 illustrates production of β-casein after 24 hrs of lactogenic hormone 
treatment. Co-cultures were grown first 2 days in the presence of EGF as a “priming” 
step, then changed to either hydrocortisone, insulin, prolactin (HIP) medium or just 
Epithelial Cells Expressing ErbB2 Homologs 13
Eagle’s Dulbecco-modified medium, both in the absence of EGF. A Northern blot 
(Fig. 3A) shows β-casein mRNA with HIP-stimulated cells expressing only a neutral 
vector, but much less in mouse c-erbB2 or HER2-expressing cultures, while NeuT 
totally blocks expression of the β-casein. Unstimulated cells produce only tiny 
amounts of β-casein mRNA, but in the same proportions as the HIP treated cultures 
(Fig. 3A).  
A Western blot employing β-casein-specific antibody (Fig. 3B), demonstrated the 
same result. No β-casein protein was detectable in cultures not receiving HIP, and no 
synthesis of the protein was apparent with 31E/HER2 or 31E/NeuT cells. Production 
by mouse c-erbB2-expressing cells was sharply reduced when compared to normal 
co-cultures or dominant negative mutant HER2-expressing co-cultures (Fig. 3B). 
Interestingly, a sharp inhibition of β-casein production occurred whenever HIP 
stimulation was combined with EGF. 
Another measure of differentiation recognizable in Line 31E cells in pure culture is 
the production of “domes”. Fig. 4A & B show that while both normal Line 31E and 
mutant HER2-expressing cells form these domes or bubbles caused by vectorial 
water transport in a polarized cell monolayer, cells expressing ErbB2 homologs lack 
this characteristic (Fig. 4C, D & E). Cells infected with mouse c-erbB2 in phase 
contrast resemble early monolayers of normal Line 31E (Fig. 4D), while HER2 and 
NeuT-infected cells exhibit clusters or foci of rounded cells on a normal-appearing 
monolayer (Fig. 4C & E). In fact, both HER2 and NeuT infected Line 31E cells 
demonstrate in longer-term culture (6 days) cord-like structures made up of 
fibroblast-like cells overlying normal-appearing epithelial cells (Fig. 4F). This latter 
phenomenon is probably the result of epithelial-mesenchymal transition among a 
fraction of the infected cells.   
The oncogenic effect of NeuT expression in Line 31E cells is demonstrated in Fig. 5 
with colony formation in soft Noble agar. Matrigel suspension culture provided 
essentially the same results (data not shown). About 20% of the c-erbB2 and HER2-
expressing cells form colonies of up to about 16 cells. While approximately 50% of 
the NeuT-infected Line 31E cells produce only the same tiny colonies seen with wild 
type HER2 and mouse c-erbB2 cells, larger, looser colonies consisting of up to 
hundreds of cells made up another 50% of the total. Giant colonies of thousands of 
cells were very rarely seen, as illustrated in the lower right panel. We also examined 
growth rate for Line 31E cells on the plastic dishes and compared with the ErbB2 
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homolog-expressing cells. There was no significant difference in the growth rates 
over a three-day period, although in long term culture, NeuT-infected cells achieved 
much higher maximum densities (data not shown). 
Various authors have described an EMT-like phenotype in ErbB2-expressing cells.11, 
12 Since EMT is characteristically associated with downregulation of E-cadherin, we 
prepared total RNA from normal and ErbB2-expressing Line 31E cells and performed 
Northern blots, probing for E-cadherin. The results are shown in Fig. 6. Taking 
advantage of the loose adherence of the fibroblast-like over-growing cells which 
appear in late culture with HER2 and NeuT-expressing cells (see Fig. 4, lower right-
hand picture) we were able to achieve an isolation and enrichment of these EMT-like 
cells. These were designated wild type HER2 “floaters” (wtfl) or NeuT “floaters” 
(NeuTfl), and were analyzed in the Northern blot next to the “parental” Line 
31E/HER2 and 31E/NeuT samples (Fig. 6). A striking downregulation could be 
observed in the “floaters” which was, however, not seen in the adherent underlying 
“parental” cells. Similarly, when blots were probed for connexin 43, clear 
downregulation was apparent in the EMT-like cell population (Fig. 6). Ethidium 
bromide staining of 18 S ribosomal RNA in the total RNA serves as an equal loading 
control.   
Table 2 provides biophysical confirmation of the morphological evidence. The 
transepithelial monolayer resistance (TER) reflects the density of tight junctions 
between the cells which hinder ion movement between electrodes placed on either 
side of the monolayer. The values shown are the product of the resistance values 
obtained (Ohms) multiplied by the area of the monolayer, and indicate that HER2 and 
NeuT-infected Line 31E monolayers are essentially non-polarized; while mouse c-
erbB2 infection leads to partial de-polarization. It is interesting that the more adherent 
cultures of Line 31E/HER2 and 31E/NeuT show high levels of E-cadherin and 
connexin 43 expression in Northern blot as compared to very low expression in 
“floaters”. Even so, transmonolayer resistance measurements show a significant loss 
of functional cell polarization in both HER2 and NeuT-infected cultures. 
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Discussion 
 
Our Line 31E in vitro differentiation model is a cloned mouse mammary epithelial cell 
line. Our investigation has demonstrated similar phenotypic effects produced by 
different ErbB2 homologs, forming a sort of hierarchy in which the mutated NeuT 
shows the strongest oncogenic effects. The mouse c-erbB2 proto-oncogene exhibits 
nonetheless characteristics similar to other members of the ErbB2 group.  The results 
presented above clearly demonstrate that expression of functional ErbB2 homologs 
influences signalling and biological phenotype. Modest changes in basal 
phosphorylation of Akt/PKB and of ERK 1/2 were evident in cells expressing mouse 
c-erbB2, HER2 and NeuT. However, the response to added EGF ligand remained 
intact. Our results show a hierarchy of effects with the different homologs consistent 
with the known fact of mutation in NeuT.5 For the first time, the mouse c-erbB2 
product has been investigated and found to be quite similar to HER2, both in terms of 
signalling characteristics, and phenotypic effects on over-expressing cells. 
The main phenotypic effects of ErbB2 homolog expression were apparent changes in 
behaviour of the epithelial cell monolayer visible in phase contrast microscopy, but 
also biophysically in the lowered transmonolayer electrical resistance (Table 2). Most 
striking was the biological effect, a partial or complete block in lactogenic hormone 
responsiveness, i.e. in the formation of domes, and in synthesis of β-casein (Figs. 3 
and 4). More directly related to oncogenic properties, only the NeuT expressing Line 
31E cells demonstrated the ability to induce efficient colony formation, both in soft 
agar and in Matrigel. Neither senescence nor apoptosis was observed. 
We observed an EMT-like effect in consequence of HER2 and NeuT expression in 
Line 31E cells. This effect was apparent in the appearance of a morphologically 
different, fibroblast-like cell type which could be isolated based on its weak 
adherence. Clones of these cells, however, consistently gave rise to cell populations 
comprising both the adherent epithelial and weakly adherent fibroblast-like 
phenotype. The fibroblast-like cell type exhibited downregulation of both E-cadherin 
and connexin 43. In this respect, our results shown in Fig. 6 closely corresponded to 
those reported recently by Jenndahl et al.11 for E-cadherin. Similarly, disturbances in 
gap junctional communication and connexin 43 function have been previously 
reported as a consequence of ErbB2 expression.13-15 
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Hynes et al.27 reported that the induction of β-casein in HC11 mouse mammary 
epithelial cells by the lactogenic hormones insulin, prolactin and the glucocorticoid, 
dexamethasone is not suppressed by oncogenic human ErbB2 or NeuT signalling, 
but is blocked by EGFR activation. Our results with Line 31E disagree in that NeuT 
caused a sharp inhibition in β-casein production, as evidenced with both Northern 
and Western blot methods. In our model as in theirs, however, EGF effected a total 
block in β-casein synthesis.  
In order to investigate the function of ErbB2 during normal breast development, 
Jones and Stern28 inactivated endogenous ErbB2 signalling through expression of a 
dominant negative truncated ErbB2 transgene during mouse mammary gland 
development. They found that normal ErbB2 signalling is required for the terminal 
stages of lobuloalveolar development and lactation as measured by the observation 
of inhibited alveolar growth and non-secreting lobuloalveoli under transgene 
expression.28 In other in vivo experiments, the influence of oncogenic rat NeuT on 
mouse mammary gland development has also been studied in transgenic mice 
overexpressing NeuT.29 Expression of the oncogene in this model is controlled by the 
MMTV-LTR promoter, leading to its elevated expression during late pregnancy and 
throughout lactation. NeuT transgene expression was assessed at lactation and early 
involution and revealed to be restricted to morphologically transformed cells, whereas 
no endogenous mouse c-erbB2 was detected in wild-type glands. NeuT-expressing 
tumor cells completely failed to express the milk proteins β-casein and WAP at 
lactation or during involution.29   
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Figure Legends: 
 
Fig. 1:  The basal expression of ErbB2 homologs, PKB/Akt protein, phospho PKB/Akt 
(serine 473) and phospho-ERK 1/2 MAP kinase was assayed using Western blots. 
The levels expressed were evaluated for control, uninfected Line 31E cells (Ǿ), for 
dominant negative mutant HER2 cells (mut), for mouse c-erbB2 cells (c-erb), for wild 
type HER2 cells (HER2) and for NeuT cells (NeuT). Four identical blots were 
prepared and probed with antibodies detected using chemiluminescence. 
 
Fig. 2:  Cultures of Line 31E cells infected with dominant negative mutant HER2, wild 
type HER2, mouse c-erbB2 and NeuT were treated with EGF for different times 
between 0 to 30 minutes. A set of lysates was prepared as described in Materials 
and Methods. Four identical PAGE blots were prepared and expression of different 
pathway markers was evaluated with Western blots using specific antibodies to 
PKB/Akt protein, phospho PKB/Akt, phospho ERK 1/2 and phospho PKCα (Upstate). 
The panel showing PKB/Akt protein indicates equal loading for the other panels. 
 
Fig. 3:  The differentiation response of mammary Line 31E and 30F (4:1) co-cultures 
to lactogenic hormone stimulation is shown in “A”. Line 31E cells infected with β-
galactosidase, wild type HER2, mouse c-erbB2 and NeuT retroviral vectors were 
treated with or without hydrocortisone, insulin and prolactin (HIP) for 24 hours. 
Samples were of total RNA resolved in a Northern blot and hybridized with a mouse 
β-casein-specific probe. In “B”, co-cultures were analzyed using a Western blot with 
an anti-mouse-β-casein anti-serum. Lysates of uninfected (normal) Line 31E are 
shown in comparison with the dominant negative mutant HER2, mouse c-erbB2, wild 
type HER2 and NeuT-infected co-cultures at 24 hours with no treatment (Ǿ) hormone 
stimulation, HIP either alone or with EGF. 
 
Fig. 4: Morphology of uninfected, normal Line 31E cells and cells infected with the 
ErbB2 homologs in phase contrast after 3 days in culture (A – E) and after 6 days in 
culture (F). Dome formation is seen at 3 days (after 24 hours HIP treatment) in 
normal and dominant negative mutant HER2 cells, but not apparent in parallel 
cultures of cells expressing functional c-erbB2, though small local foci of rounded 
cells can be recognized in these cultures (C – E). An EMT-like effect is observed in 
cultures of NeuT-infected cells maintained for longer times in culture (F), in which 
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fibroblastic cells overgrow the even monolayer. Such changes can also be seen in 
HER2 wild type cultures, but are absent in mouse c-erbB2 infected cultures. 
 
Fig. 5:  Soft agar colony growth of Line 31E cells expressing the various c-erbB2 
homologs is illustrated after 6 days in culture. Photographs were taken with the 5X 
objective.    
 
Fig 6:  Northern blots are presented to show the steady state expression of E-
cadherin and connexin 43 in uninfected, normal Line 31E cells (Ǿ) and at 6 weeks 
after infection with dominant negative mutant HER2, wild type HER2 (wt) and NeuT. 
Lines of loosely attached “floater” cells could be isolated by washing cultures of wild 
type HER2 and NeuT cells with a stream of medium from a pipette. These cells re-
attached and proliferated readily when sub-cultured, giving rise to the (wtfl) and 
(NeuTfl) cultures. 
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Table 1:  Mouse c-erbB2 (old) = BC046811 containing the addition 
  Mouse c-erbB2 (new) = NM_001003817 
 
 
c-erbB2(old)    2192 CCTAATCAAACGAAGGCGACAGAAGATCCGGAAGTATACCATGCGTAGGC   2241 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
c-erbB2(new)    2201 CCTAATCAAACGAAGGCGACAGAAGATCCGGAAGTATACCATGCGTAGGC   2250 
 
c-erbB2(old)    2242 TGCTGCAGGAGACCGAGGTGAGGCGTGCCGAGGGCCTCCTAGCACCCCCT   2291 
                     |||||||||||||||___________________________________ 
c-erbB2(new)    2251 TGCTGCAGGAGACCG-----------------------------------   2265 
 
c-erbB2(old)    2292 TGGCTTTGCAGCTAGCTGGGCATTCACCCTACCACCCTCTCGCTCCAGCT   2341 
                     _________________________________           __|||| 
c-erbB2(new)    2266 ----------------------------------------------AGCT   2269 
 
c-erbB2(old)    2342 GGTGGAGCCGCTGACGCCCAGTGGAGCTGTGCCCAACCAGGCTCAGATGC   2391 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
c-erbB2(new)    2270 GGTGGAGCCGCTGACGCCCAGTGGAGCTGTGCCCAACCAGGCTCAGATGC   2319 
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Table 2:   Electrical resistance across monolayers of 
  cultured Line 31E mammary epithelial cells 
 
 
 
  Cell Type     Transmonolayer resistance* 
         (Ohms x cm2) 
 
Line 31 E  Normal     420 
 
  Mutant HER2    440 
 
  Mouse c-erbB2 (Riken)   180 
 
  HER2      60 
 
  NeuT      50 
 
  Neu T monolayer from floaters    15 
___________________________________________________________________ 
*  Cultures were grown on nitrocellulose filter inserts (2.2 cm diameter) for 5 days.  
Values shown were calculated from the average of 3 measurements taken across the 
membrane from apical to basal sides with the Millicell ERS instrument. 
 
 
Epithelial Cells Expressing ErbB2 Homologs 24
 
 
Figure 1 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0        2       5      15      30
pERK1/2 (~ 42-44kDa)
pPKCα
0       2       5     15      30
(~ 82kDa)
min. of EGF stim.        0       2       5     15      30  
pAkt
mutHER2
HER2wt
c-erbB2
NeuT
(~ 60kDa)
min. of EGF stim.        0       2       5     15      30  
mutHER2
HER2wt
c-erbB2
NeuT
Akt (~ 60kDa)
Epithelial Cells Expressing ErbB2 Homologs 26
 
 
Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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